index,title,abstract,Master Ref#,PubMed ID,Journal,Primary Author,Publication Year,Volume / Issue,Pages,Priority Journal,PubMed ID:,Full Reference:,"Study Outcome ($/QALY, $/DALY, Both):",Study Country:,Disease Classification:,Intervention Type(s):,Intervention Phrase vs. Comparator Phrase:,Target Characteristics:,Max Target Age:,Min Target Age:,Target Genders:,Review:,Time Horizon:,Discounting Rate (Costs):,Discounting Rate (QALYs):,Incremental Cost-Effectiveness Ratio (Original currency and year):,Currency Country:,Currency Year:,Incremental Cost-Effectiveness Ratio (Converted to current $USD):
25601,Cost-effectiveness of iron supplementation and malaria chemoprophylaxis in the prevention of anaemia and malaria among Tanzanian infants,"Prerequisites for effective interventions against severe anaemia and malaria among infants are economic evaluations to aid the setting of priorities and the making of health policy. In the present study we analysed the cost and effectiveness of three control strategies hypothetically delivered through the Expanded Programme on Immunization (EPI). For the prevention of severe anaemia and from the perspective of the health provider, the cost-effectiveness ratios were, respectively, US$ 8, US$ 9, and US$ 21 per disability-adjusted life year (DALY) for malaria chemoprophylaxis with Deltaprim (a combination of 3.125 mg pyrimethamine and 25 mg dapsone) + iron, Deltaprim alone, or iron supplementation alone. For malaria prevention, Deltaprim + iron cost US$ 9.7 per DALY and Deltaprim alone cost US$ 10.2 per DALY. From a sociocultural perspective the cost-effectiveness ratios ranged from US$ 9 to US$ 26 for severe anaemia prevention and from US$ 11 to US$ 12 for the prevention of clinical malaria. These ratios were highly cost-effective, as defined by the World Bank's proposed threshold of less than US$ 25 per DALY for comparative assessments. Furthermore, all the preventive interventions were less costly than the current malaria and anaemia control strategies that rely on clinical case management. This economic analysis supports the inclusion of both malaria chemoprophylaxis and iron supplementation delivered through EPI as part of the control strategies for these major killers of infants in parts of sub-Saharan Africa.",2000-01-0627,10686744,Bull World Health Organ,M Alonzo Gonzalez,2000,78 / 1,97-107,No,10686744,"M Alonzo Gonzalez; C Menendez; F Font; E Kahigwa; J Kimario; H Mshinda; M Tanner; X Bosch-Capblanch; P L Alonso; MA Gonzalez; PL Alonso; Alexander Lourdes Samy; Zahra Fazli Khalaf; Wah-Yun Low; Cost-effectiveness of iron supplementation and malaria chemoprophylaxis in the prevention of anaemia and malaria among Tanzanian infants, Bull World Health Organ, ; 78(1):0042-9686; 97-107",DALY,Tanzania,Not Stated,Pharmaceutical,Inclusion of deltaprim (combination of pyrimethamine & dapsone) + iron for prevention of severe anemia through expanded programme on immunization vs. Standard/Usual Care- Standard case management,Not Stated,5 Years,Not Stated,"Female, Male",Full,,2.00,3,-5.79,United States,1996,-9.54
25602,Cost-effectiveness of iron supplementation and malaria chemoprophylaxis in the prevention of anaemia and malaria among Tanzanian infants,"Prerequisites for effective interventions against severe anaemia and malaria among infants are economic evaluations to aid the setting of priorities and the making of health policy. In the present study we analysed the cost and effectiveness of three control strategies hypothetically delivered through the Expanded Programme on Immunization (EPI). For the prevention of severe anaemia and from the perspective of the health provider, the cost-effectiveness ratios were, respectively, US$ 8, US$ 9, and US$ 21 per disability-adjusted life year (DALY) for malaria chemoprophylaxis with Deltaprim (a combination of 3.125 mg pyrimethamine and 25 mg dapsone) + iron, Deltaprim alone, or iron supplementation alone. For malaria prevention, Deltaprim + iron cost US$ 9.7 per DALY and Deltaprim alone cost US$ 10.2 per DALY. From a sociocultural perspective the cost-effectiveness ratios ranged from US$ 9 to US$ 26 for severe anaemia prevention and from US$ 11 to US$ 12 for the prevention of clinical malaria. These ratios were highly cost-effective, as defined by the World Bank's proposed threshold of less than US$ 25 per DALY for comparative assessments. Furthermore, all the preventive interventions were less costly than the current malaria and anaemia control strategies that rely on clinical case management. This economic analysis supports the inclusion of both malaria chemoprophylaxis and iron supplementation delivered through EPI as part of the control strategies for these major killers of infants in parts of sub-Saharan Africa.",2000-01-0627,10686744,Bull World Health Organ,M Alonzo Gonzalez,2000,78 / 1,97-107,No,10686744,"M Alonzo Gonzalez; C Menendez; F Font; E Kahigwa; J Kimario; H Mshinda; M Tanner; X Bosch-Capblanch; P L Alonso; MA Gonzalez; PL Alonso; Alexander Lourdes Samy; Zahra Fazli Khalaf; Wah-Yun Low; Cost-effectiveness of iron supplementation and malaria chemoprophylaxis in the prevention of anaemia and malaria among Tanzanian infants, Bull World Health Organ, ; 78(1):0042-9686; 97-107",DALY,Tanzania,Not Stated,Pharmaceutical,Inclusion of deltaprim (combination of pyrimethamine & dapsone) for prevention of severe anemia through expanded programme on immunization vs. Standard/Usual Care- Standard case management,Not Stated,5 Years,Not Stated,"Female, Male",Full,,2.00,3,-6.47,United States,1996,-10.68
25603,Cost-effectiveness of iron supplementation and malaria chemoprophylaxis in the prevention of anaemia and malaria among Tanzanian infants,"Prerequisites for effective interventions against severe anaemia and malaria among infants are economic evaluations to aid the setting of priorities and the making of health policy. In the present study we analysed the cost and effectiveness of three control strategies hypothetically delivered through the Expanded Programme on Immunization (EPI). For the prevention of severe anaemia and from the perspective of the health provider, the cost-effectiveness ratios were, respectively, US$ 8, US$ 9, and US$ 21 per disability-adjusted life year (DALY) for malaria chemoprophylaxis with Deltaprim (a combination of 3.125 mg pyrimethamine and 25 mg dapsone) + iron, Deltaprim alone, or iron supplementation alone. For malaria prevention, Deltaprim + iron cost US$ 9.7 per DALY and Deltaprim alone cost US$ 10.2 per DALY. From a sociocultural perspective the cost-effectiveness ratios ranged from US$ 9 to US$ 26 for severe anaemia prevention and from US$ 11 to US$ 12 for the prevention of clinical malaria. These ratios were highly cost-effective, as defined by the World Bank's proposed threshold of less than US$ 25 per DALY for comparative assessments. Furthermore, all the preventive interventions were less costly than the current malaria and anaemia control strategies that rely on clinical case management. This economic analysis supports the inclusion of both malaria chemoprophylaxis and iron supplementation delivered through EPI as part of the control strategies for these major killers of infants in parts of sub-Saharan Africa.",2000-01-0627,10686744,Bull World Health Organ,M Alonzo Gonzalez,2000,78 / 1,97-107,No,10686744,"M Alonzo Gonzalez; C Menendez; F Font; E Kahigwa; J Kimario; H Mshinda; M Tanner; X Bosch-Capblanch; P L Alonso; MA Gonzalez; PL Alonso; Alexander Lourdes Samy; Zahra Fazli Khalaf; Wah-Yun Low; Cost-effectiveness of iron supplementation and malaria chemoprophylaxis in the prevention of anaemia and malaria among Tanzanian infants, Bull World Health Organ, ; 78(1):0042-9686; 97-107",DALY,Tanzania,Not Stated,Pharmaceutical,Inclusion of iron supplemetation for prevention of severe anemia through expanded programme on immunization vs. Standard/Usual Care- Standard case management,Not Stated,5 Years,Not Stated,"Female, Male",Full,,2.00,3,-5.78,United States,1996,-9.53
25604,Cost-effectiveness of iron supplementation and malaria chemoprophylaxis in the prevention of anaemia and malaria among Tanzanian infants,"Prerequisites for effective interventions against severe anaemia and malaria among infants are economic evaluations to aid the setting of priorities and the making of health policy. In the present study we analysed the cost and effectiveness of three control strategies hypothetically delivered through the Expanded Programme on Immunization (EPI). For the prevention of severe anaemia and from the perspective of the health provider, the cost-effectiveness ratios were, respectively, US$ 8, US$ 9, and US$ 21 per disability-adjusted life year (DALY) for malaria chemoprophylaxis with Deltaprim (a combination of 3.125 mg pyrimethamine and 25 mg dapsone) + iron, Deltaprim alone, or iron supplementation alone. For malaria prevention, Deltaprim + iron cost US$ 9.7 per DALY and Deltaprim alone cost US$ 10.2 per DALY. From a sociocultural perspective the cost-effectiveness ratios ranged from US$ 9 to US$ 26 for severe anaemia prevention and from US$ 11 to US$ 12 for the prevention of clinical malaria. These ratios were highly cost-effective, as defined by the World Bank's proposed threshold of less than US$ 25 per DALY for comparative assessments. Furthermore, all the preventive interventions were less costly than the current malaria and anaemia control strategies that rely on clinical case management. This economic analysis supports the inclusion of both malaria chemoprophylaxis and iron supplementation delivered through EPI as part of the control strategies for these major killers of infants in parts of sub-Saharan Africa.",2000-01-0627,10686744,Bull World Health Organ,M Alonzo Gonzalez,2000,78 / 1,97-107,No,10686744,"M Alonzo Gonzalez; C Menendez; F Font; E Kahigwa; J Kimario; H Mshinda; M Tanner; X Bosch-Capblanch; P L Alonso; MA Gonzalez; PL Alonso; Alexander Lourdes Samy; Zahra Fazli Khalaf; Wah-Yun Low; Cost-effectiveness of iron supplementation and malaria chemoprophylaxis in the prevention of anaemia and malaria among Tanzanian infants, Bull World Health Organ, ; 78(1):0042-9686; 97-107",DALY,Tanzania,Not Stated,Pharmaceutical,Deltaprim (combination of pyrimethamine & dapsone) + iron for prevention of malaria through expanded programme on immunization vs. Standard/Usual Care- Standard case management,Not Stated,5 Years,Not Stated,"Female, Male",Full,,2.00,3,-6.87,United States,1996,-11.34
25605,Cost-effectiveness of iron supplementation and malaria chemoprophylaxis in the prevention of anaemia and malaria among Tanzanian infants,"Prerequisites for effective interventions against severe anaemia and malaria among infants are economic evaluations to aid the setting of priorities and the making of health policy. In the present study we analysed the cost and effectiveness of three control strategies hypothetically delivered through the Expanded Programme on Immunization (EPI). For the prevention of severe anaemia and from the perspective of the health provider, the cost-effectiveness ratios were, respectively, US$ 8, US$ 9, and US$ 21 per disability-adjusted life year (DALY) for malaria chemoprophylaxis with Deltaprim (a combination of 3.125 mg pyrimethamine and 25 mg dapsone) + iron, Deltaprim alone, or iron supplementation alone. For malaria prevention, Deltaprim + iron cost US$ 9.7 per DALY and Deltaprim alone cost US$ 10.2 per DALY. From a sociocultural perspective the cost-effectiveness ratios ranged from US$ 9 to US$ 26 for severe anaemia prevention and from US$ 11 to US$ 12 for the prevention of clinical malaria. These ratios were highly cost-effective, as defined by the World Bank's proposed threshold of less than US$ 25 per DALY for comparative assessments. Furthermore, all the preventive interventions were less costly than the current malaria and anaemia control strategies that rely on clinical case management. This economic analysis supports the inclusion of both malaria chemoprophylaxis and iron supplementation delivered through EPI as part of the control strategies for these major killers of infants in parts of sub-Saharan Africa.",2000-01-0627,10686744,Bull World Health Organ,M Alonzo Gonzalez,2000,78 / 1,97-107,No,10686744,"M Alonzo Gonzalez; C Menendez; F Font; E Kahigwa; J Kimario; H Mshinda; M Tanner; X Bosch-Capblanch; P L Alonso; MA Gonzalez; PL Alonso; Alexander Lourdes Samy; Zahra Fazli Khalaf; Wah-Yun Low; Cost-effectiveness of iron supplementation and malaria chemoprophylaxis in the prevention of anaemia and malaria among Tanzanian infants, Bull World Health Organ, ; 78(1):0042-9686; 97-107",DALY,Tanzania,Not Stated,Pharmaceutical,Deltaprim (combination of pyrimethamine & dapsone) for prevention of malaria through expanded programme on immunization vs. Standard/Usual Care- Standard case management,Not Stated,5 Years,Not Stated,"Female, Male",Full,,2.00,3,-7.8,United States,1996,-12.87
25606,Meningococcal vaccination for adolescents? An economic evaluation in Victoria,"To undertake an economic evaluation of the options for vaccination of adolescents using meningococcal polysaccharide vaccine based on Victorian data.Cost-effectiveness and cost-benefit analyses of three options for vaccination were undertaken for hypothetical populations aged 15-19 years. Baseline analyses assumed a single year of programme implementation and vaccine protection of 5 years. Sensitivity analyses of key variables were performed. Outcomes included the number of people vaccinated, cases averted, life years saved and disability adjusted life years (DALY) averted. Lost earnings avoided were included as a measure of vaccination benefit in cost-benefit analyses.Vaccination of people in Years 10-12 (secondary school) and first year university within a defined population with a high rate of disease was the most cost-effective option. Excluding direct cost savings and compared with no vaccination, this resulted in a discounted cost per DALY avoided of $17646 and benefits exceeding costs in discounted terms. The 'break-even' incidence rate for this option in the cost-benefit analysis was 11.9/100000.Economic evidence favours the use of vaccination within well-defined populations with a high rate of disease.",2001-01-0535,11885733,J Paediatr Child Health,S A Skull,2001,37 / 5,S28-33,No,11885733,"S A Skull; J R Butler; Steven M. Albert; Jane Bear-Lehman; Stewart J. Anderson; Meningococcal vaccination for adolescents? An economic evaluation in Victoria, J Paediatr Child Health, ; 37(5):1034-4810; S28-33",DALY,Australia,Not Stated,Immunization,Administration of one dose of menigococcal vaccine at programme commencement in students in years 10-12 and first year university vs. None,"regional population, high disease incidence",40 Years,12 Years,"Female, Male",Full,,5.00,5,17646,Australia,1999,17690.93
25607,Meningococcal vaccination for adolescents? An economic evaluation in Victoria,"To undertake an economic evaluation of the options for vaccination of adolescents using meningococcal polysaccharide vaccine based on Victorian data.Cost-effectiveness and cost-benefit analyses of three options for vaccination were undertaken for hypothetical populations aged 15-19 years. Baseline analyses assumed a single year of programme implementation and vaccine protection of 5 years. Sensitivity analyses of key variables were performed. Outcomes included the number of people vaccinated, cases averted, life years saved and disability adjusted life years (DALY) averted. Lost earnings avoided were included as a measure of vaccination benefit in cost-benefit analyses.Vaccination of people in Years 10-12 (secondary school) and first year university within a defined population with a high rate of disease was the most cost-effective option. Excluding direct cost savings and compared with no vaccination, this resulted in a discounted cost per DALY avoided of $17646 and benefits exceeding costs in discounted terms. The 'break-even' incidence rate for this option in the cost-benefit analysis was 11.9/100000.Economic evidence favours the use of vaccination within well-defined populations with a high rate of disease.",2001-01-0535,11885733,J Paediatr Child Health,S A Skull,2001,37 / 5,S28-33,No,11885733,"S A Skull; J R Butler; Steven M. Albert; Jane Bear-Lehman; Stewart J. Anderson; Meningococcal vaccination for adolescents? An economic evaluation in Victoria, J Paediatr Child Health, ; 37(5):1034-4810; S28-33",DALY,Australia,Not Stated,Immunization,Administration of one dose of menigococcal vaccine at programme commencement in students in year 12 vs. None,"large population approximating a state or territory, lower disease incidence",40 Years,12 Years,"Female, Male",Full,,5.00,5,52955,Australia,1999,53089.83
25608,Meningococcal vaccination for adolescents? An economic evaluation in Victoria,"To undertake an economic evaluation of the options for vaccination of adolescents using meningococcal polysaccharide vaccine based on Victorian data.Cost-effectiveness and cost-benefit analyses of three options for vaccination were undertaken for hypothetical populations aged 15-19 years. Baseline analyses assumed a single year of programme implementation and vaccine protection of 5 years. Sensitivity analyses of key variables were performed. Outcomes included the number of people vaccinated, cases averted, life years saved and disability adjusted life years (DALY) averted. Lost earnings avoided were included as a measure of vaccination benefit in cost-benefit analyses.Vaccination of people in Years 10-12 (secondary school) and first year university within a defined population with a high rate of disease was the most cost-effective option. Excluding direct cost savings and compared with no vaccination, this resulted in a discounted cost per DALY avoided of $17646 and benefits exceeding costs in discounted terms. The 'break-even' incidence rate for this option in the cost-benefit analysis was 11.9/100000.Economic evidence favours the use of vaccination within well-defined populations with a high rate of disease.",2001-01-0535,11885733,J Paediatr Child Health,S A Skull,2001,37 / 5,S28-33,No,11885733,"S A Skull; J R Butler; Steven M. Albert; Jane Bear-Lehman; Stewart J. Anderson; Meningococcal vaccination for adolescents? An economic evaluation in Victoria, J Paediatr Child Health, ; 37(5):1034-4810; S28-33",DALY,Australia,Not Stated,Immunization,Administration of one dose of menigococcal vaccine at programme commencement in students in Years 10-12 and first year university from a defined regional population with high disease incidence and vaccination of all year 12 students in large population approximating a state or territory with lower disease incidence vs. None,Not Stated,40 Years,12 Years,"Female, Male",Full,,5.00,5,42114,Australia,1999,42221.23
25609,The economics of HIV vaccines: projecting the impact of HIV vaccination of infants in sub-Saharan Africa,"Objectives: (i) To project vaccine parameters, economic consequences and market size associated with HIV-1 vaccination of infants in sub-Saharan Africa through the Expanded Program on Immunisation (EPI); and (ii) to assess threshold values for price and effectiveness. Study design and methods: Cost-effectiveness analysis using a decision-analysis model linking epidemiological data with economic information. Epidemiological data on the burden of disease of HIV were obtained from the World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS. The decision analysis model was constructed using estimates of lifetime chances of HIV infection. To assess threshold values for price and effectiveness, a maximum value for cost effectiveness in developing countries of $US100 was used in the base case. One-way and multivariate sensitivity analysis was performed on relevant parameters, assessing the impact of these parameters on the results of our analysis. In the base case, health benefits and consequences were discounted at a rate of 3%. Study perspective: Societal. Results: According to our model, introduction of an HIV-1 vaccine in the EPI would result in the vaccination of 8717112 infants in sub-Saharan Africa per year. This corresponds to the prevention of 1839355 cases of HIV per year, gaining 16461800 disability-adjusted life years (DALYs). The cost-effectiveness ratio of the intervention would be $US3.4 per DALY gained (1998 values) at a vaccine price in the base case of $US5. At the same price the estimated size of the market would be approximately $US44536111 per year. Conclusion: If technological and financial problems associated with the development of an HIV vaccine can be solved, HIV vaccination in Africa could be both cost effective and potentially profitable.",2001-01-0553,11700780,Pharmacoeconomics,J M Bos,2001,19 / 9,937-46,Yes,11700780,"J M Bos; M J Postma; JM Bos; MJ Postma; Andreas Lundin; Alma Sorberg Wallin; Daniel Falkstedt; Peter Allebeck; Tomas Hemmingsson; The economics of HIV vaccines: projecting the impact of HIV vaccination of infants in sub-Saharan Africa, Pharmacoeconomics, ; 19(9):1179-2027; 937-46",DALY,"Benin, Botswana, Burundi, Cameroon, Central African Republic, Chad, Congo Democratic Republic, Djibouti, Ethiopia, Kenya, Liberia, Madagascar, Malawi, Mali, Namibia, Niger, Nigeria, Senegal, Sierra Leone, Somalia, South Africa, Sudan, Swaziland, Tanzania, Togo, Uganda, Zimbabwe",Not Stated,Immunization,HIV vaccination through the Expanded Program on Immunisation (EPI) vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,Not Stated,3,3.4,United States,1998,5.4
25610,Efficacy and cost-effectiveness of environmental management for malaria control,"Roll back malaria (RBM) aims at halving the current burden of the disease by the year 2010. The focus is on sub-Saharan Africa, and it is proposed to implement efficacious and cost-effective control strategies. But the evidence base of such information is scarce, and a notable missing element is the discussion of the potential of environmental management. We reviewed the literature and identified multiple malaria control programmes that incorporated environmental management as the central feature. Prominent among them are programmes launched in 1929 and implemented for two decades at copper mining communities in Zambia. The full package of control measures consisted of vegetation clearance, modification of river boundaries, draining swamps, oil application to open water bodies and house screening. Part of the population also was given quinine and was sleeping under mosquito nets. Monthly malaria incidence rates and vector densities were used for surveillance and adaptive tuning of the environmental management strategies to achieve a high level of performance. Within 3-5 years, malaria-related mortality, morbidity and incidence rates were reduced by 70-95%. Over the entire 20 years of implementation, the programme had averted an estimated 4173 deaths and 161,205 malaria attacks. The estimated costs per death and malaria attack averted were US$ 858 and US$ 22.20, respectively. Over the initial 3-5 years start-up period, analogous to the short-duration of cost-effectiveness analyses of current studies, we estimated that the costs per disability adjusted life year (DALY) averted were US$ 524-591. However, the strategy has a track record of becoming cost-effective in the longer term, as maintenance costs were much lower: US$ 22-92 per DALY averted. In view of fewer adverse ecological effects, increased sustainability and better uses of local resources and knowledge, environmental management--integrated with pharmacological, insecticidal and bednet interventions--could substantially increase the chances of rolling back malaria.",2001-01-02875,11555434,Trop Med Int Health,J Utzinger,2001,6 / 9,677-87,No,11555434,"J Utzinger; Y Tozan; B H Singer; Efficacy and cost-effectiveness of environmental management for malaria control, Trop Med Int Health, 2001-Sep; 6(9):1360-2276; 677-87",DALY,Zambia,Not Stated,Environmental,"Environmental management consisting of vegetation clearance, modification of river bounderies, draining swamps, oil application to open water bodies and house screening in copper mining communities vs. Standard/Usual Care- Assumed care",Not Stated,Not Stated,19 Years,"Female, Male",Full,", 20 years",Not Stated,3,524.24,United States,1995,890.28
25611,Cost-effectiveness analysis of dialysis and kidney transplants in Japan,"Although kidney transplantation is considered to be more desirable than dialysis in terms of cost-effectiveness and patients' quality of life, there have been very few cases of kidney transplants in Japan. This study was conducted to compare the cost-effectiveness of dialysis and kidney transplants using Disability-Adjusted Life Years (DALYs) as an indicator of effectiveness. Most data necessary for the DALYs analysis were obtained from publications. The disability weights for dialysis patients and kidney transplant patients were estimated based on a questionnaire e-mailed to medical officials of the Japanese Government. Expected duration of treatment was estimated from the survival rates of dialysis patients and the graft-survival rates of transplant patients using the Weibull model method. The cost of dialysis and living-related donor (LRD) transplant included only medical expenditures and neglected all other costs, and the cost of cadaveric donor (CAD) transplant included the budget for organ procurement and distribution in addition to medical expenditures. The analysis showed that dialysis averted 138,019 DALYs/year, living-related donor transplant averted 5,740 DALYs/year, and CAD transplant averted 1,892 DALYs/year. The cost-effectiveness ratio (C-E ratio) was 9,546 thousand yen/DALY for dialysis, 1,809 thousand yen/DALY for LRD transplant, and 2,322 thousand yen/DALY for CAD transplant. These results could be used for the decision making of the Government on what resources should be allocated to the promotion of kidney transplantation. Also, the methodology used in this study can be applied to cost-effectiveness analysis of other organ transplants.",2001-01-0566,11450591,Keio J Med,M Kaminota,2001,50 / 2,100-8,No,11450591,"M Kaminota; Alexandra P. Saltman; Frank L. Silver; Jiming Fang; Melissa Stamplecoski; Moira K. Kapral; Cost-effectiveness analysis of dialysis and kidney transplants in Japan, Keio J Med, ; 50(2):0022-9717; 100-8",DALY,Japan,Not Stated,Medical Procedure,Dialysis vs. None,Not Stated,Not Stated,6 Years,"Female, Male",Full,,3.00,3,9546000,Japan,1996,144855.06
25612,Cost-effectiveness analysis of dialysis and kidney transplants in Japan,"Although kidney transplantation is considered to be more desirable than dialysis in terms of cost-effectiveness and patients' quality of life, there have been very few cases of kidney transplants in Japan. This study was conducted to compare the cost-effectiveness of dialysis and kidney transplants using Disability-Adjusted Life Years (DALYs) as an indicator of effectiveness. Most data necessary for the DALYs analysis were obtained from publications. The disability weights for dialysis patients and kidney transplant patients were estimated based on a questionnaire e-mailed to medical officials of the Japanese Government. Expected duration of treatment was estimated from the survival rates of dialysis patients and the graft-survival rates of transplant patients using the Weibull model method. The cost of dialysis and living-related donor (LRD) transplant included only medical expenditures and neglected all other costs, and the cost of cadaveric donor (CAD) transplant included the budget for organ procurement and distribution in addition to medical expenditures. The analysis showed that dialysis averted 138,019 DALYs/year, living-related donor transplant averted 5,740 DALYs/year, and CAD transplant averted 1,892 DALYs/year. The cost-effectiveness ratio (C-E ratio) was 9,546 thousand yen/DALY for dialysis, 1,809 thousand yen/DALY for LRD transplant, and 2,322 thousand yen/DALY for CAD transplant. These results could be used for the decision making of the Government on what resources should be allocated to the promotion of kidney transplantation. Also, the methodology used in this study can be applied to cost-effectiveness analysis of other organ transplants.",2001-01-0566,11450591,Keio J Med,M Kaminota,2001,50 / 2,100-8,No,11450591,"M Kaminota; Alexandra P. Saltman; Frank L. Silver; Jiming Fang; Melissa Stamplecoski; Moira K. Kapral; Cost-effectiveness analysis of dialysis and kidney transplants in Japan, Keio J Med, ; 50(2):0022-9717; 100-8",DALY,Japan,Not Stated,Medical Procedure,Dialysis and kidney transplant of cadaveric donor vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,2322000,Japan,1996,35235.01
25613,Cost-effectiveness analysis of dialysis and kidney transplants in Japan,"Although kidney transplantation is considered to be more desirable than dialysis in terms of cost-effectiveness and patients' quality of life, there have been very few cases of kidney transplants in Japan. This study was conducted to compare the cost-effectiveness of dialysis and kidney transplants using Disability-Adjusted Life Years (DALYs) as an indicator of effectiveness. Most data necessary for the DALYs analysis were obtained from publications. The disability weights for dialysis patients and kidney transplant patients were estimated based on a questionnaire e-mailed to medical officials of the Japanese Government. Expected duration of treatment was estimated from the survival rates of dialysis patients and the graft-survival rates of transplant patients using the Weibull model method. The cost of dialysis and living-related donor (LRD) transplant included only medical expenditures and neglected all other costs, and the cost of cadaveric donor (CAD) transplant included the budget for organ procurement and distribution in addition to medical expenditures. The analysis showed that dialysis averted 138,019 DALYs/year, living-related donor transplant averted 5,740 DALYs/year, and CAD transplant averted 1,892 DALYs/year. The cost-effectiveness ratio (C-E ratio) was 9,546 thousand yen/DALY for dialysis, 1,809 thousand yen/DALY for LRD transplant, and 2,322 thousand yen/DALY for CAD transplant. These results could be used for the decision making of the Government on what resources should be allocated to the promotion of kidney transplantation. Also, the methodology used in this study can be applied to cost-effectiveness analysis of other organ transplants.",2001-01-0566,11450591,Keio J Med,M Kaminota,2001,50 / 2,100-8,No,11450591,"M Kaminota; Alexandra P. Saltman; Frank L. Silver; Jiming Fang; Melissa Stamplecoski; Moira K. Kapral; Cost-effectiveness analysis of dialysis and kidney transplants in Japan, Keio J Med, ; 50(2):0022-9717; 100-8",DALY,Japan,Not Stated,Medical Procedure,Dialysis and kidney transplant of living related donor vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,1809000,Japan,1996,27450.53
25614,Should programmes for community-level meningococcal vaccination be considered in Australia? An economic evaluation,"BACKGROUND: Disease due to serogroup C Neisseria meningitidis is life-threatening and potentially preventable by vaccination. In 1999, the UK instigated mass vaccination after a sustained increase in serogroup C meningococcal disease. In the same year, Victoria, Australia experienced a similar change in disease epidemiology. It is timely to undertake an economic evaluation of options for community vaccination in Australia based on local data. METHODS: Cost-effectiveness and cost-benefit analyses of three options for use of polysaccharide vaccine were undertaken for a hypothetical population aged 15--19 years. Baseline analyses assumed 5 years' duration of vaccine protection following a single year of programme implementation. Sensitivity analyses of key variables were performed, including vaccine coverage and effectiveness, case fatality rate and the discount rate. Outcomes included the number of people vaccinated, cases averted, life-years saved and disability-adjusted life-years (DALY) averted. Cost-benefit analysis used lost earnings avoided as a measure of vaccination benefit. RESULTS: Vaccination of people aged 15--19 years in a defined population with a high rate of disease was the most cost-effective option. Compared with no vaccination and assuming 5 years' duration of protection and exclusion of direct cost savings, this resulted in a discounted cost per life-year saved of $23,623, a cost per DALY avoided of $21,097 and benefits exceeding costs in discounted terms. The 'break-even' incidence rate for this option with exclusion of direct cost savings was 14.0/100,000. CONCLUSIONS: Community use of polysaccharide vaccination may be cost effective in Australia under certain conditions. Economic evidence favours use of vaccination in well-defined populations with a high rate of disease. Policy decision-making also requires consideration of non-economic factors, including feasibility of implementation and risk perception by the community.",2001-01-02873,11416085,Int J Epidemiol,S A Skull,2001,30 / 3,571-8; discussion 578-9,No,11416085,"S A Skull; J R Butler; P Robinson; J Carnie; Should programmes for community-level meningococcal vaccination be considered in Australia? An economic evaluation, Int J Epidemiol, 2001-Jun; 30(3):0300-5771; 571-8; discussion 578-9",DALY,Australia,Not Stated,Immunization,Meningococcal vaccination of students in years 10-12 and first year university from a defined regional population with a high incidence of disease vs. None,Not Stated,40 Years,12 Years,"Female, Male",Full,,5.00,5,21097,Australia,1999,21150.72
25615,Should programmes for community-level meningococcal vaccination be considered in Australia? An economic evaluation,"BACKGROUND: Disease due to serogroup C Neisseria meningitidis is life-threatening and potentially preventable by vaccination. In 1999, the UK instigated mass vaccination after a sustained increase in serogroup C meningococcal disease. In the same year, Victoria, Australia experienced a similar change in disease epidemiology. It is timely to undertake an economic evaluation of options for community vaccination in Australia based on local data. METHODS: Cost-effectiveness and cost-benefit analyses of three options for use of polysaccharide vaccine were undertaken for a hypothetical population aged 15--19 years. Baseline analyses assumed 5 years' duration of vaccine protection following a single year of programme implementation. Sensitivity analyses of key variables were performed, including vaccine coverage and effectiveness, case fatality rate and the discount rate. Outcomes included the number of people vaccinated, cases averted, life-years saved and disability-adjusted life-years (DALY) averted. Cost-benefit analysis used lost earnings avoided as a measure of vaccination benefit. RESULTS: Vaccination of people aged 15--19 years in a defined population with a high rate of disease was the most cost-effective option. Compared with no vaccination and assuming 5 years' duration of protection and exclusion of direct cost savings, this resulted in a discounted cost per life-year saved of $23,623, a cost per DALY avoided of $21,097 and benefits exceeding costs in discounted terms. The 'break-even' incidence rate for this option with exclusion of direct cost savings was 14.0/100,000. CONCLUSIONS: Community use of polysaccharide vaccination may be cost effective in Australia under certain conditions. Economic evidence favours use of vaccination in well-defined populations with a high rate of disease. Policy decision-making also requires consideration of non-economic factors, including feasibility of implementation and risk perception by the community.",2001-01-02873,11416085,Int J Epidemiol,S A Skull,2001,30 / 3,571-8; discussion 578-9,No,11416085,"S A Skull; J R Butler; P Robinson; J Carnie; Should programmes for community-level meningococcal vaccination be considered in Australia? An economic evaluation, Int J Epidemiol, 2001-Jun; 30(3):0300-5771; 571-8; discussion 578-9",DALY,Australia,Not Stated,Immunization,Meningococcal vaccination of all year 12 students in a larger population with a lower incidence vs. Meningococcal vaccination of students in years 10-12 and first-year university from a defined regional population with high disease incidence,Not Stated,40 Years,12 Years,"Female, Male",Full,,5.00,5,177494,Australia,1999,177945.93
25616,Should programmes for community-level meningococcal vaccination be considered in Australia? An economic evaluation,"BACKGROUND: Disease due to serogroup C Neisseria meningitidis is life-threatening and potentially preventable by vaccination. In 1999, the UK instigated mass vaccination after a sustained increase in serogroup C meningococcal disease. In the same year, Victoria, Australia experienced a similar change in disease epidemiology. It is timely to undertake an economic evaluation of options for community vaccination in Australia based on local data. METHODS: Cost-effectiveness and cost-benefit analyses of three options for use of polysaccharide vaccine were undertaken for a hypothetical population aged 15--19 years. Baseline analyses assumed 5 years' duration of vaccine protection following a single year of programme implementation. Sensitivity analyses of key variables were performed, including vaccine coverage and effectiveness, case fatality rate and the discount rate. Outcomes included the number of people vaccinated, cases averted, life-years saved and disability-adjusted life-years (DALY) averted. Cost-benefit analysis used lost earnings avoided as a measure of vaccination benefit. RESULTS: Vaccination of people aged 15--19 years in a defined population with a high rate of disease was the most cost-effective option. Compared with no vaccination and assuming 5 years' duration of protection and exclusion of direct cost savings, this resulted in a discounted cost per life-year saved of $23,623, a cost per DALY avoided of $21,097 and benefits exceeding costs in discounted terms. The 'break-even' incidence rate for this option with exclusion of direct cost savings was 14.0/100,000. CONCLUSIONS: Community use of polysaccharide vaccination may be cost effective in Australia under certain conditions. Economic evidence favours use of vaccination in well-defined populations with a high rate of disease. Policy decision-making also requires consideration of non-economic factors, including feasibility of implementation and risk perception by the community.",2001-01-02873,11416085,Int J Epidemiol,S A Skull,2001,30 / 3,571-8; discussion 578-9,No,11416085,"S A Skull; J R Butler; P Robinson; J Carnie; Should programmes for community-level meningococcal vaccination be considered in Australia? An economic evaluation, Int J Epidemiol, 2001-Jun; 30(3):0300-5771; 571-8; discussion 578-9",DALY,Australia,Not Stated,Immunization,Meningococcal vaccination of students in years 10-12 and first-year university students from a defined regional population with high disease incidence and vaccination of all year 12 students in large population approximating a state or territory with lower disease incidence vs. Meningococcal vaccination of students in years 10-12 and first-year university from a defined regional population with high disease incidence,Not Stated,40 Years,12 Years,"Female, Male",Full,,5.00,5,82007,Australia,1999,82215.8
25617,Should programmes for community-level meningococcal vaccination be considered in Australia? An economic evaluation,"BACKGROUND: Disease due to serogroup C Neisseria meningitidis is life-threatening and potentially preventable by vaccination. In 1999, the UK instigated mass vaccination after a sustained increase in serogroup C meningococcal disease. In the same year, Victoria, Australia experienced a similar change in disease epidemiology. It is timely to undertake an economic evaluation of options for community vaccination in Australia based on local data. METHODS: Cost-effectiveness and cost-benefit analyses of three options for use of polysaccharide vaccine were undertaken for a hypothetical population aged 15--19 years. Baseline analyses assumed 5 years' duration of vaccine protection following a single year of programme implementation. Sensitivity analyses of key variables were performed, including vaccine coverage and effectiveness, case fatality rate and the discount rate. Outcomes included the number of people vaccinated, cases averted, life-years saved and disability-adjusted life-years (DALY) averted. Cost-benefit analysis used lost earnings avoided as a measure of vaccination benefit. RESULTS: Vaccination of people aged 15--19 years in a defined population with a high rate of disease was the most cost-effective option. Compared with no vaccination and assuming 5 years' duration of protection and exclusion of direct cost savings, this resulted in a discounted cost per life-year saved of $23,623, a cost per DALY avoided of $21,097 and benefits exceeding costs in discounted terms. The 'break-even' incidence rate for this option with exclusion of direct cost savings was 14.0/100,000. CONCLUSIONS: Community use of polysaccharide vaccination may be cost effective in Australia under certain conditions. Economic evidence favours use of vaccination in well-defined populations with a high rate of disease. Policy decision-making also requires consideration of non-economic factors, including feasibility of implementation and risk perception by the community.",2001-01-02873,11416085,Int J Epidemiol,S A Skull,2001,30 / 3,571-8; discussion 578-9,No,11416085,"S A Skull; J R Butler; P Robinson; J Carnie; Should programmes for community-level meningococcal vaccination be considered in Australia? An economic evaluation, Int J Epidemiol, 2001-Jun; 30(3):0300-5771; 571-8; discussion 578-9",DALY,Australia,Not Stated,Immunization,Meningococcal vaccination of students in years 10-12 and first-year university students from a defined regional population with high disease incidence and vaccination of all year 12 students in large population approximating a state or territory with lower disease incidence vs. None,Not Stated,40 Years,12 Years,"Female, Male",Full,,5.00,5,55766,Australia,1999,55907.99
25618,Should programmes for community-level meningococcal vaccination be considered in Australia? An economic evaluation,"BACKGROUND: Disease due to serogroup C Neisseria meningitidis is life-threatening and potentially preventable by vaccination. In 1999, the UK instigated mass vaccination after a sustained increase in serogroup C meningococcal disease. In the same year, Victoria, Australia experienced a similar change in disease epidemiology. It is timely to undertake an economic evaluation of options for community vaccination in Australia based on local data. METHODS: Cost-effectiveness and cost-benefit analyses of three options for use of polysaccharide vaccine were undertaken for a hypothetical population aged 15--19 years. Baseline analyses assumed 5 years' duration of vaccine protection following a single year of programme implementation. Sensitivity analyses of key variables were performed, including vaccine coverage and effectiveness, case fatality rate and the discount rate. Outcomes included the number of people vaccinated, cases averted, life-years saved and disability-adjusted life-years (DALY) averted. Cost-benefit analysis used lost earnings avoided as a measure of vaccination benefit. RESULTS: Vaccination of people aged 15--19 years in a defined population with a high rate of disease was the most cost-effective option. Compared with no vaccination and assuming 5 years' duration of protection and exclusion of direct cost savings, this resulted in a discounted cost per life-year saved of $23,623, a cost per DALY avoided of $21,097 and benefits exceeding costs in discounted terms. The 'break-even' incidence rate for this option with exclusion of direct cost savings was 14.0/100,000. CONCLUSIONS: Community use of polysaccharide vaccination may be cost effective in Australia under certain conditions. Economic evidence favours use of vaccination in well-defined populations with a high rate of disease. Policy decision-making also requires consideration of non-economic factors, including feasibility of implementation and risk perception by the community.",2001-01-02873,11416085,Int J Epidemiol,S A Skull,2001,30 / 3,571-8; discussion 578-9,No,11416085,"S A Skull; J R Butler; P Robinson; J Carnie; Should programmes for community-level meningococcal vaccination be considered in Australia? An economic evaluation, Int J Epidemiol, 2001-Jun; 30(3):0300-5771; 571-8; discussion 578-9",DALY,Australia,Not Stated,Immunization,Meningococcal vaccination of all year 12 students in a larger population with a lower incidence vs. None,Not Stated,40 Years,12 Years,"Female, Male",Full,,5.00,5,74554,Australia,1999,74743.83
25619,Cost-benefit analysis of a PMTCT program in Mozambique,"The costs and benefits of a HlV/AIDS PMTCT program in a Mozambican city were calculated. The provision and non-provision of infant feeding formula were considered, along with voluntary counselling and testing, and anti-retroviral treatment with Nevirapine. Costs were calculated in monetary units and benefits as deaths averted and disability-adjusted life years. The UNAIDS cost-effectiveness tool for evaluating ARV drug and substitute feeding intervention was used. The costs of the program were compared with the costs of treating HIV-infected children. With no infant feeding formula, there would be a total savings of US$5242 and a negative cost per DALY of US$1.53 without infant feeding formula, With formula, net annual costs would be US$141,268 and cost per DALY US$38.69. Citywide, each year 132 infant deaths would be averted by use of Nevirapine and eight averted by the breastmilk replacement program. All program optins have reasonable cost-effectiveness ratios. (C) 2002 Elsevier Science Ltd. All rights reserved.",2002-01-03554,0,Eval. Program Plan.,D Peffer,2002,25 / 4,433-445,No,Not Stated,"D Peffer; J. J. Fernandez-Munoz; A. Moron-Verdasco; M. Cigaran-Mendez; E. Munoz-Hellin; M. Perez-de-Heredia-Torres; C. Fernandez-de-las-Penas; Marcelo Cunio Machado Fonseca; Gabriela Tannus Branco de Araujo; Helder Etto; Alexandre Schiola; Natalia Santoni; Marcio Machado; Antonio Abellan; Angel Rodriguez-Laso; Rogelio Pujol; Laura Barrios; NB Osman; P Vaz; PA Allotey; DD Reidpath; L Reichenbach; SJ Yoon; H Lee; Y Shin; YI Kim; CY Kim; HJ Chang; P Crettaz; D Pennington; L Rhomberg; K Brand; O Jolliet; A Tauxe; P Hofstetter; JK Hammitt; L Segall; LK Lane; R Blostein; KM Iburg; F Kamper-Jorgensen; Cost-benefit analysis of a PMTCT program in Mozambique, Eval. Program Plan., ; 25(4):0149-7189; 433-445",DALY,Mozambique,Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Pharmaceutical",Program to prevent mother-to-child HIV transmission vs. None,Pregnant women in an urban population going for their first antenatal consulation and HIV-positive children,Not Stated,19 Years,Female,Full,,3.00,3,38.69,United States,2000,58.15
25620,Cost-benefit analysis of a PMTCT program in Mozambique,"The costs and benefits of a HlV/AIDS PMTCT program in a Mozambican city were calculated. The provision and non-provision of infant feeding formula were considered, along with voluntary counselling and testing, and anti-retroviral treatment with Nevirapine. Costs were calculated in monetary units and benefits as deaths averted and disability-adjusted life years. The UNAIDS cost-effectiveness tool for evaluating ARV drug and substitute feeding intervention was used. The costs of the program were compared with the costs of treating HIV-infected children. With no infant feeding formula, there would be a total savings of US$5242 and a negative cost per DALY of US$1.53 without infant feeding formula, With formula, net annual costs would be US$141,268 and cost per DALY US$38.69. Citywide, each year 132 infant deaths would be averted by use of Nevirapine and eight averted by the breastmilk replacement program. All program optins have reasonable cost-effectiveness ratios. (C) 2002 Elsevier Science Ltd. All rights reserved.",2002-01-03554,0,Eval. Program Plan.,D Peffer,2002,25 / 4,433-445,No,Not Stated,"D Peffer; J. J. Fernandez-Munoz; A. Moron-Verdasco; M. Cigaran-Mendez; E. Munoz-Hellin; M. Perez-de-Heredia-Torres; C. Fernandez-de-las-Penas; Marcelo Cunio Machado Fonseca; Gabriela Tannus Branco de Araujo; Helder Etto; Alexandre Schiola; Natalia Santoni; Marcio Machado; Antonio Abellan; Angel Rodriguez-Laso; Rogelio Pujol; Laura Barrios; NB Osman; P Vaz; PA Allotey; DD Reidpath; L Reichenbach; SJ Yoon; H Lee; Y Shin; YI Kim; CY Kim; HJ Chang; P Crettaz; D Pennington; L Rhomberg; K Brand; O Jolliet; A Tauxe; P Hofstetter; JK Hammitt; L Segall; LK Lane; R Blostein; KM Iburg; F Kamper-Jorgensen; Cost-benefit analysis of a PMTCT program in Mozambique, Eval. Program Plan., ; 25(4):0149-7189; 433-445",DALY,Mozambique,Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Pharmaceutical",Program to prevent mother-to-child HIV transmission vs. None,Pregnant women in an urban population going for their first antenatal consulation and HIV-positive children,Not Stated,19 Years,Female,Full,,3.00,3,Not Stated,United States,2000,Not Stated
25621,Tuberculosis control priorities defined by using cost-effectiveness and burden of disease,"OBJECTIVE: To define TB control priorities using cost-effectiveness and burden of disease. METHODS: An assumed cohort of 2,000 cases was set up based on age-specific incidence of 794 newly registered smear-positive cases in Beijing in 1994. Prognostic trees and model diagrams of infectivity with natural history and DOTS intervention were constructed based on the epidemiological parameters. RESULTS: DOTS reduced 89.19% of YLL, 78.90% of YLD, and 99.98% of infectivity BOD. One DALY could be saved with 45.70 Yuan by DOTS with 3% discount. Sensitivity analysis showed that discount had effect on CER. Weight of age was insensitive to CER. The higher the DOTS cured rate, the more the cost-effectiveness. CONCLUSIONS: DOTS is a good cost-effectiveness TB control strategy. Cost-effectiveness and burden of disease can be used to define TB control priorities.",2002-99-00939,12244758,Biomed Environ Sci,Qun Xu,2002,15 / 2,172-6,No,12244758,"Qun Xu; Zheng-Lai Wu; Shui-Gao Jin; Li-Xing Zhang; Tuberculosis control priorities defined by using cost-effectiveness and burden of disease, Biomed Environ Sci, 2002-Jun; 15(2):0895-3988; 172-6",DALY,China,Not Stated,"Care Delivery, Diagnostic, Pharmaceutical","DOTS (directly observed treatment, short-course) vs. Standard/Usual Care",Not Stated,64 Years,6 Years,"Female, Male",Full,Not Stated / None,3.00,3,45.7,China,2000,8.3
25622,Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies,"The objective of this study was to provide conservative estimates of the global and regional effectiveness and cost-effectiveness of tobacco control policies. Using a static model of the cohort of smokers alive in 1995, we estimated the number of smoking-attributable deaths that could be averted by: (1) price increases, (2) nicotine replacement therapy (NRT), and (3) a package of non-price interventions other than NRT. We calculated the cost-effectiveness of these policy interventions by weighing the approximate public-sector costs against the years of healthy life saved, measured in disability-adjusted life years, or DALYs. Even with deliberately conservative assumptions, tax increases that would raise the real price of cigarettes by 10% worldwide would prevent between 5 and 16 million tobacco-related deaths, and could cost 3-70 US dollars per DALY saved in low-income and middle-income regions. NRT and a package of non-price interventions other than NRT are also cost-effective in low-income and middle-income regions, at 280-870 US dollars per DALY and 36-710 US dollars per DALY, respectively. In high-income countries, price increases were found to have a cost-effectiveness of 83-2771 US dollars per DALY, NRT 750-7206 US dollars per DALY and other non-price interventions 696-13,924 US dollars per DALY. Tobacco control policies, particularly tax increases on cigarettes, are cost-effective relative to other health interventions. Our estimates are subject to considerable variation in actual settings; thus, local cost-effectiveness studies are required to guide local policy.",2002-01-0508,12215240,Nicotine Tob Res,M Kent Ranson,2002,4 / 3,311-9,No,12215240,"M Kent Ranson; Prabhat Jha; Frank J Chaloupka; Son N Nguyen; Reem M. Ghandour; Meg Comeau; Carol Tobias; Beth Dworetzky; Rose Hamershock; Lynda Honberg; Marie Y. Mann; Sara S. Bachman; Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies, Nicotine Tob Res, ; 4(3):1462-2203; 311-9",DALY,Not Stated,Not Stated,"Health Education or Behavior, Legislation / Regulation, Pharmaceutical",Price increase of cigarettes by 10% (low-end estimate) vs. None,current smokers,Not Stated,Not Stated,"Female, Male",Full,", 50",3.00,3,2,United States,1997,3.23
25623,Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies,"The objective of this study was to provide conservative estimates of the global and regional effectiveness and cost-effectiveness of tobacco control policies. Using a static model of the cohort of smokers alive in 1995, we estimated the number of smoking-attributable deaths that could be averted by: (1) price increases, (2) nicotine replacement therapy (NRT), and (3) a package of non-price interventions other than NRT. We calculated the cost-effectiveness of these policy interventions by weighing the approximate public-sector costs against the years of healthy life saved, measured in disability-adjusted life years, or DALYs. Even with deliberately conservative assumptions, tax increases that would raise the real price of cigarettes by 10% worldwide would prevent between 5 and 16 million tobacco-related deaths, and could cost 3-70 US dollars per DALY saved in low-income and middle-income regions. NRT and a package of non-price interventions other than NRT are also cost-effective in low-income and middle-income regions, at 280-870 US dollars per DALY and 36-710 US dollars per DALY, respectively. In high-income countries, price increases were found to have a cost-effectiveness of 83-2771 US dollars per DALY, NRT 750-7206 US dollars per DALY and other non-price interventions 696-13,924 US dollars per DALY. Tobacco control policies, particularly tax increases on cigarettes, are cost-effective relative to other health interventions. Our estimates are subject to considerable variation in actual settings; thus, local cost-effectiveness studies are required to guide local policy.",2002-01-0508,12215240,Nicotine Tob Res,M Kent Ranson,2002,4 / 3,311-9,No,12215240,"M Kent Ranson; Prabhat Jha; Frank J Chaloupka; Son N Nguyen; Reem M. Ghandour; Meg Comeau; Carol Tobias; Beth Dworetzky; Rose Hamershock; Lynda Honberg; Marie Y. Mann; Sara S. Bachman; Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies, Nicotine Tob Res, ; 4(3):1462-2203; 311-9",DALY,Not Stated,Not Stated,"Health Education or Behavior, Legislation / Regulation, Pharmaceutical",Price increase of cigarettes by 10% (low-end estimate) vs. None,current smokers,Not Stated,Not Stated,"Female, Male",Full,", 50",3.00,3,3,United States,1997,4.84
25624,Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies,"The objective of this study was to provide conservative estimates of the global and regional effectiveness and cost-effectiveness of tobacco control policies. Using a static model of the cohort of smokers alive in 1995, we estimated the number of smoking-attributable deaths that could be averted by: (1) price increases, (2) nicotine replacement therapy (NRT), and (3) a package of non-price interventions other than NRT. We calculated the cost-effectiveness of these policy interventions by weighing the approximate public-sector costs against the years of healthy life saved, measured in disability-adjusted life years, or DALYs. Even with deliberately conservative assumptions, tax increases that would raise the real price of cigarettes by 10% worldwide would prevent between 5 and 16 million tobacco-related deaths, and could cost 3-70 US dollars per DALY saved in low-income and middle-income regions. NRT and a package of non-price interventions other than NRT are also cost-effective in low-income and middle-income regions, at 280-870 US dollars per DALY and 36-710 US dollars per DALY, respectively. In high-income countries, price increases were found to have a cost-effectiveness of 83-2771 US dollars per DALY, NRT 750-7206 US dollars per DALY and other non-price interventions 696-13,924 US dollars per DALY. Tobacco control policies, particularly tax increases on cigarettes, are cost-effective relative to other health interventions. Our estimates are subject to considerable variation in actual settings; thus, local cost-effectiveness studies are required to guide local policy.",2002-01-0508,12215240,Nicotine Tob Res,M Kent Ranson,2002,4 / 3,311-9,No,12215240,"M Kent Ranson; Prabhat Jha; Frank J Chaloupka; Son N Nguyen; Reem M. Ghandour; Meg Comeau; Carol Tobias; Beth Dworetzky; Rose Hamershock; Lynda Honberg; Marie Y. Mann; Sara S. Bachman; Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies, Nicotine Tob Res, ; 4(3):1462-2203; 311-9",DALY,Not Stated,Not Stated,"Health Education or Behavior, Legislation / Regulation, Pharmaceutical",Price increase of cigarettes by 10% (low-end estimate) vs. None,current smokers,Not Stated,Not Stated,"Female, Male",Full,", 50",3.00,3,7,United States,1997,11.29
25625,Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies,"The objective of this study was to provide conservative estimates of the global and regional effectiveness and cost-effectiveness of tobacco control policies. Using a static model of the cohort of smokers alive in 1995, we estimated the number of smoking-attributable deaths that could be averted by: (1) price increases, (2) nicotine replacement therapy (NRT), and (3) a package of non-price interventions other than NRT. We calculated the cost-effectiveness of these policy interventions by weighing the approximate public-sector costs against the years of healthy life saved, measured in disability-adjusted life years, or DALYs. Even with deliberately conservative assumptions, tax increases that would raise the real price of cigarettes by 10% worldwide would prevent between 5 and 16 million tobacco-related deaths, and could cost 3-70 US dollars per DALY saved in low-income and middle-income regions. NRT and a package of non-price interventions other than NRT are also cost-effective in low-income and middle-income regions, at 280-870 US dollars per DALY and 36-710 US dollars per DALY, respectively. In high-income countries, price increases were found to have a cost-effectiveness of 83-2771 US dollars per DALY, NRT 750-7206 US dollars per DALY and other non-price interventions 696-13,924 US dollars per DALY. Tobacco control policies, particularly tax increases on cigarettes, are cost-effective relative to other health interventions. Our estimates are subject to considerable variation in actual settings; thus, local cost-effectiveness studies are required to guide local policy.",2002-01-0508,12215240,Nicotine Tob Res,M Kent Ranson,2002,4 / 3,311-9,No,12215240,"M Kent Ranson; Prabhat Jha; Frank J Chaloupka; Son N Nguyen; Reem M. Ghandour; Meg Comeau; Carol Tobias; Beth Dworetzky; Rose Hamershock; Lynda Honberg; Marie Y. Mann; Sara S. Bachman; Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies, Nicotine Tob Res, ; 4(3):1462-2203; 311-9",DALY,Not Stated,Not Stated,"Health Education or Behavior, Legislation / Regulation, Pharmaceutical",Price increase of cigarettes by 10% (low-end estimate) vs. None,current smokers,Not Stated,Not Stated,"Female, Male",Full,", 50",3.00,3,5,United States,1997,8.06
25626,Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies,"The objective of this study was to provide conservative estimates of the global and regional effectiveness and cost-effectiveness of tobacco control policies. Using a static model of the cohort of smokers alive in 1995, we estimated the number of smoking-attributable deaths that could be averted by: (1) price increases, (2) nicotine replacement therapy (NRT), and (3) a package of non-price interventions other than NRT. We calculated the cost-effectiveness of these policy interventions by weighing the approximate public-sector costs against the years of healthy life saved, measured in disability-adjusted life years, or DALYs. Even with deliberately conservative assumptions, tax increases that would raise the real price of cigarettes by 10% worldwide would prevent between 5 and 16 million tobacco-related deaths, and could cost 3-70 US dollars per DALY saved in low-income and middle-income regions. NRT and a package of non-price interventions other than NRT are also cost-effective in low-income and middle-income regions, at 280-870 US dollars per DALY and 36-710 US dollars per DALY, respectively. In high-income countries, price increases were found to have a cost-effectiveness of 83-2771 US dollars per DALY, NRT 750-7206 US dollars per DALY and other non-price interventions 696-13,924 US dollars per DALY. Tobacco control policies, particularly tax increases on cigarettes, are cost-effective relative to other health interventions. Our estimates are subject to considerable variation in actual settings; thus, local cost-effectiveness studies are required to guide local policy.",2002-01-0508,12215240,Nicotine Tob Res,M Kent Ranson,2002,4 / 3,311-9,No,12215240,"M Kent Ranson; Prabhat Jha; Frank J Chaloupka; Son N Nguyen; Reem M. Ghandour; Meg Comeau; Carol Tobias; Beth Dworetzky; Rose Hamershock; Lynda Honberg; Marie Y. Mann; Sara S. Bachman; Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies, Nicotine Tob Res, ; 4(3):1462-2203; 311-9",DALY,Not Stated,Not Stated,"Health Education or Behavior, Legislation / Regulation, Pharmaceutical",Price increase of cigarettes by 10% (low-end estimate) vs. None,current smokers,Not Stated,Not Stated,"Female, Male",Full,", 50",3.00,3,1,United States,1997,1.61
25627,Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies,"The objective of this study was to provide conservative estimates of the global and regional effectiveness and cost-effectiveness of tobacco control policies. Using a static model of the cohort of smokers alive in 1995, we estimated the number of smoking-attributable deaths that could be averted by: (1) price increases, (2) nicotine replacement therapy (NRT), and (3) a package of non-price interventions other than NRT. We calculated the cost-effectiveness of these policy interventions by weighing the approximate public-sector costs against the years of healthy life saved, measured in disability-adjusted life years, or DALYs. Even with deliberately conservative assumptions, tax increases that would raise the real price of cigarettes by 10% worldwide would prevent between 5 and 16 million tobacco-related deaths, and could cost 3-70 US dollars per DALY saved in low-income and middle-income regions. NRT and a package of non-price interventions other than NRT are also cost-effective in low-income and middle-income regions, at 280-870 US dollars per DALY and 36-710 US dollars per DALY, respectively. In high-income countries, price increases were found to have a cost-effectiveness of 83-2771 US dollars per DALY, NRT 750-7206 US dollars per DALY and other non-price interventions 696-13,924 US dollars per DALY. Tobacco control policies, particularly tax increases on cigarettes, are cost-effective relative to other health interventions. Our estimates are subject to considerable variation in actual settings; thus, local cost-effectiveness studies are required to guide local policy.",2002-01-0508,12215240,Nicotine Tob Res,M Kent Ranson,2002,4 / 3,311-9,No,12215240,"M Kent Ranson; Prabhat Jha; Frank J Chaloupka; Son N Nguyen; Reem M. Ghandour; Meg Comeau; Carol Tobias; Beth Dworetzky; Rose Hamershock; Lynda Honberg; Marie Y. Mann; Sara S. Bachman; Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies, Nicotine Tob Res, ; 4(3):1462-2203; 311-9",DALY,Not Stated,Not Stated,"Health Education or Behavior, Legislation / Regulation, Pharmaceutical",Price increase of cigarettes by 10% (low-end estimate) vs. None,current smokers,Not Stated,Not Stated,"Female, Male",Full,", 50",3.00,3,2,United States,1997,3.23
25628,Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies,"The objective of this study was to provide conservative estimates of the global and regional effectiveness and cost-effectiveness of tobacco control policies. Using a static model of the cohort of smokers alive in 1995, we estimated the number of smoking-attributable deaths that could be averted by: (1) price increases, (2) nicotine replacement therapy (NRT), and (3) a package of non-price interventions other than NRT. We calculated the cost-effectiveness of these policy interventions by weighing the approximate public-sector costs against the years of healthy life saved, measured in disability-adjusted life years, or DALYs. Even with deliberately conservative assumptions, tax increases that would raise the real price of cigarettes by 10% worldwide would prevent between 5 and 16 million tobacco-related deaths, and could cost 3-70 US dollars per DALY saved in low-income and middle-income regions. NRT and a package of non-price interventions other than NRT are also cost-effective in low-income and middle-income regions, at 280-870 US dollars per DALY and 36-710 US dollars per DALY, respectively. In high-income countries, price increases were found to have a cost-effectiveness of 83-2771 US dollars per DALY, NRT 750-7206 US dollars per DALY and other non-price interventions 696-13,924 US dollars per DALY. Tobacco control policies, particularly tax increases on cigarettes, are cost-effective relative to other health interventions. Our estimates are subject to considerable variation in actual settings; thus, local cost-effectiveness studies are required to guide local policy.",2002-01-0508,12215240,Nicotine Tob Res,M Kent Ranson,2002,4 / 3,311-9,No,12215240,"M Kent Ranson; Prabhat Jha; Frank J Chaloupka; Son N Nguyen; Reem M. Ghandour; Meg Comeau; Carol Tobias; Beth Dworetzky; Rose Hamershock; Lynda Honberg; Marie Y. Mann; Sara S. Bachman; Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies, Nicotine Tob Res, ; 4(3):1462-2203; 311-9",DALY,Not Stated,Not Stated,"Health Education or Behavior, Legislation / Regulation, Pharmaceutical",Price increase of cigarettes by 10% (low-end estimate) vs. None,current smokers,Not Stated,Not Stated,"Female, Male",Full,", 50",3.00,3,3,United States,1997,4.84
25629,Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies,"The objective of this study was to provide conservative estimates of the global and regional effectiveness and cost-effectiveness of tobacco control policies. Using a static model of the cohort of smokers alive in 1995, we estimated the number of smoking-attributable deaths that could be averted by: (1) price increases, (2) nicotine replacement therapy (NRT), and (3) a package of non-price interventions other than NRT. We calculated the cost-effectiveness of these policy interventions by weighing the approximate public-sector costs against the years of healthy life saved, measured in disability-adjusted life years, or DALYs. Even with deliberately conservative assumptions, tax increases that would raise the real price of cigarettes by 10% worldwide would prevent between 5 and 16 million tobacco-related deaths, and could cost 3-70 US dollars per DALY saved in low-income and middle-income regions. NRT and a package of non-price interventions other than NRT are also cost-effective in low-income and middle-income regions, at 280-870 US dollars per DALY and 36-710 US dollars per DALY, respectively. In high-income countries, price increases were found to have a cost-effectiveness of 83-2771 US dollars per DALY, NRT 750-7206 US dollars per DALY and other non-price interventions 696-13,924 US dollars per DALY. Tobacco control policies, particularly tax increases on cigarettes, are cost-effective relative to other health interventions. Our estimates are subject to considerable variation in actual settings; thus, local cost-effectiveness studies are required to guide local policy.",2002-01-0508,12215240,Nicotine Tob Res,M Kent Ranson,2002,4 / 3,311-9,No,12215240,"M Kent Ranson; Prabhat Jha; Frank J Chaloupka; Son N Nguyen; Reem M. Ghandour; Meg Comeau; Carol Tobias; Beth Dworetzky; Rose Hamershock; Lynda Honberg; Marie Y. Mann; Sara S. Bachman; Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies, Nicotine Tob Res, ; 4(3):1462-2203; 311-9",DALY,Not Stated,Not Stated,"Health Education or Behavior, Legislation / Regulation, Pharmaceutical",Price increase of cigarettes by 10% (low-end estimate) vs. None,current smokers,Not Stated,Not Stated,"Female, Male",Full,", 50",3.00,3,83,United States,1997,133.84
25630,Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies,"The objective of this study was to provide conservative estimates of the global and regional effectiveness and cost-effectiveness of tobacco control policies. Using a static model of the cohort of smokers alive in 1995, we estimated the number of smoking-attributable deaths that could be averted by: (1) price increases, (2) nicotine replacement therapy (NRT), and (3) a package of non-price interventions other than NRT. We calculated the cost-effectiveness of these policy interventions by weighing the approximate public-sector costs against the years of healthy life saved, measured in disability-adjusted life years, or DALYs. Even with deliberately conservative assumptions, tax increases that would raise the real price of cigarettes by 10% worldwide would prevent between 5 and 16 million tobacco-related deaths, and could cost 3-70 US dollars per DALY saved in low-income and middle-income regions. NRT and a package of non-price interventions other than NRT are also cost-effective in low-income and middle-income regions, at 280-870 US dollars per DALY and 36-710 US dollars per DALY, respectively. In high-income countries, price increases were found to have a cost-effectiveness of 83-2771 US dollars per DALY, NRT 750-7206 US dollars per DALY and other non-price interventions 696-13,924 US dollars per DALY. Tobacco control policies, particularly tax increases on cigarettes, are cost-effective relative to other health interventions. Our estimates are subject to considerable variation in actual settings; thus, local cost-effectiveness studies are required to guide local policy.",2002-01-0508,12215240,Nicotine Tob Res,M Kent Ranson,2002,4 / 3,311-9,No,12215240,"M Kent Ranson; Prabhat Jha; Frank J Chaloupka; Son N Nguyen; Reem M. Ghandour; Meg Comeau; Carol Tobias; Beth Dworetzky; Rose Hamershock; Lynda Honberg; Marie Y. Mann; Sara S. Bachman; Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies, Nicotine Tob Res, ; 4(3):1462-2203; 311-9",DALY,Not Stated,Not Stated,"Health Education or Behavior, Legislation / Regulation, Pharmaceutical",Price increase of cigarettes by 10% (low-end estimate) vs. None,current smokers,Not Stated,Not Stated,"Female, Male",Full,", 50",3.00,3,12,United States,1997,19.35
25631,Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies,"The objective of this study was to provide conservative estimates of the global and regional effectiveness and cost-effectiveness of tobacco control policies. Using a static model of the cohort of smokers alive in 1995, we estimated the number of smoking-attributable deaths that could be averted by: (1) price increases, (2) nicotine replacement therapy (NRT), and (3) a package of non-price interventions other than NRT. We calculated the cost-effectiveness of these policy interventions by weighing the approximate public-sector costs against the years of healthy life saved, measured in disability-adjusted life years, or DALYs. Even with deliberately conservative assumptions, tax increases that would raise the real price of cigarettes by 10% worldwide would prevent between 5 and 16 million tobacco-related deaths, and could cost 3-70 US dollars per DALY saved in low-income and middle-income regions. NRT and a package of non-price interventions other than NRT are also cost-effective in low-income and middle-income regions, at 280-870 US dollars per DALY and 36-710 US dollars per DALY, respectively. In high-income countries, price increases were found to have a cost-effectiveness of 83-2771 US dollars per DALY, NRT 750-7206 US dollars per DALY and other non-price interventions 696-13,924 US dollars per DALY. Tobacco control policies, particularly tax increases on cigarettes, are cost-effective relative to other health interventions. Our estimates are subject to considerable variation in actual settings; thus, local cost-effectiveness studies are required to guide local policy.",2002-01-0508,12215240,Nicotine Tob Res,M Kent Ranson,2002,4 / 3,311-9,No,12215240,"M Kent Ranson; Prabhat Jha; Frank J Chaloupka; Son N Nguyen; Reem M. Ghandour; Meg Comeau; Carol Tobias; Beth Dworetzky; Rose Hamershock; Lynda Honberg; Marie Y. Mann; Sara S. Bachman; Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies, Nicotine Tob Res, ; 4(3):1462-2203; 311-9",DALY,Not Stated,Not Stated,"Health Education or Behavior, Legislation / Regulation, Pharmaceutical",Nicotine replacement therapy (NRT) with effectiveness of 2.5% (low-end estimate) vs. None,current smokers,Not Stated,Not Stated,"Female, Male",Full,", 50",3.00,3,335,United States,1997,540.2
25632,Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies,"The objective of this study was to provide conservative estimates of the global and regional effectiveness and cost-effectiveness of tobacco control policies. Using a static model of the cohort of smokers alive in 1995, we estimated the number of smoking-attributable deaths that could be averted by: (1) price increases, (2) nicotine replacement therapy (NRT), and (3) a package of non-price interventions other than NRT. We calculated the cost-effectiveness of these policy interventions by weighing the approximate public-sector costs against the years of healthy life saved, measured in disability-adjusted life years, or DALYs. Even with deliberately conservative assumptions, tax increases that would raise the real price of cigarettes by 10% worldwide would prevent between 5 and 16 million tobacco-related deaths, and could cost 3-70 US dollars per DALY saved in low-income and middle-income regions. NRT and a package of non-price interventions other than NRT are also cost-effective in low-income and middle-income regions, at 280-870 US dollars per DALY and 36-710 US dollars per DALY, respectively. In high-income countries, price increases were found to have a cost-effectiveness of 83-2771 US dollars per DALY, NRT 750-7206 US dollars per DALY and other non-price interventions 696-13,924 US dollars per DALY. Tobacco control policies, particularly tax increases on cigarettes, are cost-effective relative to other health interventions. Our estimates are subject to considerable variation in actual settings; thus, local cost-effectiveness studies are required to guide local policy.",2002-01-0508,12215240,Nicotine Tob Res,M Kent Ranson,2002,4 / 3,311-9,No,12215240,"M Kent Ranson; Prabhat Jha; Frank J Chaloupka; Son N Nguyen; Reem M. Ghandour; Meg Comeau; Carol Tobias; Beth Dworetzky; Rose Hamershock; Lynda Honberg; Marie Y. Mann; Sara S. Bachman; Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies, Nicotine Tob Res, ; 4(3):1462-2203; 311-9",DALY,Not Stated,Not Stated,"Health Education or Behavior, Legislation / Regulation, Pharmaceutical",Nicotine replacement therapy (NRT) with effectiveness of 2.5% (low-end estimate) vs. None,current smokers,Not Stated,Not Stated,"Female, Male",Full,", 50",3.00,3,229,United States,1997,369.27
25633,Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies,"The objective of this study was to provide conservative estimates of the global and regional effectiveness and cost-effectiveness of tobacco control policies. Using a static model of the cohort of smokers alive in 1995, we estimated the number of smoking-attributable deaths that could be averted by: (1) price increases, (2) nicotine replacement therapy (NRT), and (3) a package of non-price interventions other than NRT. We calculated the cost-effectiveness of these policy interventions by weighing the approximate public-sector costs against the years of healthy life saved, measured in disability-adjusted life years, or DALYs. Even with deliberately conservative assumptions, tax increases that would raise the real price of cigarettes by 10% worldwide would prevent between 5 and 16 million tobacco-related deaths, and could cost 3-70 US dollars per DALY saved in low-income and middle-income regions. NRT and a package of non-price interventions other than NRT are also cost-effective in low-income and middle-income regions, at 280-870 US dollars per DALY and 36-710 US dollars per DALY, respectively. In high-income countries, price increases were found to have a cost-effectiveness of 83-2771 US dollars per DALY, NRT 750-7206 US dollars per DALY and other non-price interventions 696-13,924 US dollars per DALY. Tobacco control policies, particularly tax increases on cigarettes, are cost-effective relative to other health interventions. Our estimates are subject to considerable variation in actual settings; thus, local cost-effectiveness studies are required to guide local policy.",2002-01-0508,12215240,Nicotine Tob Res,M Kent Ranson,2002,4 / 3,311-9,No,12215240,"M Kent Ranson; Prabhat Jha; Frank J Chaloupka; Son N Nguyen; Reem M. Ghandour; Meg Comeau; Carol Tobias; Beth Dworetzky; Rose Hamershock; Lynda Honberg; Marie Y. Mann; Sara S. Bachman; Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies, Nicotine Tob Res, ; 4(3):1462-2203; 311-9",DALY,Not Stated,Not Stated,"Health Education or Behavior, Legislation / Regulation, Pharmaceutical",Nicotine replacement therapy (NRT) with effectiveness of 2.5% (low-end estimate) vs. None,current smokers,Not Stated,Not Stated,"Female, Male",Full,", 50",3.00,3,241,United States,1997,388.62
25634,Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies,"The objective of this study was to provide conservative estimates of the global and regional effectiveness and cost-effectiveness of tobacco control policies. Using a static model of the cohort of smokers alive in 1995, we estimated the number of smoking-attributable deaths that could be averted by: (1) price increases, (2) nicotine replacement therapy (NRT), and (3) a package of non-price interventions other than NRT. We calculated the cost-effectiveness of these policy interventions by weighing the approximate public-sector costs against the years of healthy life saved, measured in disability-adjusted life years, or DALYs. Even with deliberately conservative assumptions, tax increases that would raise the real price of cigarettes by 10% worldwide would prevent between 5 and 16 million tobacco-related deaths, and could cost 3-70 US dollars per DALY saved in low-income and middle-income regions. NRT and a package of non-price interventions other than NRT are also cost-effective in low-income and middle-income regions, at 280-870 US dollars per DALY and 36-710 US dollars per DALY, respectively. In high-income countries, price increases were found to have a cost-effectiveness of 83-2771 US dollars per DALY, NRT 750-7206 US dollars per DALY and other non-price interventions 696-13,924 US dollars per DALY. Tobacco control policies, particularly tax increases on cigarettes, are cost-effective relative to other health interventions. Our estimates are subject to considerable variation in actual settings; thus, local cost-effectiveness studies are required to guide local policy.",2002-01-0508,12215240,Nicotine Tob Res,M Kent Ranson,2002,4 / 3,311-9,No,12215240,"M Kent Ranson; Prabhat Jha; Frank J Chaloupka; Son N Nguyen; Reem M. Ghandour; Meg Comeau; Carol Tobias; Beth Dworetzky; Rose Hamershock; Lynda Honberg; Marie Y. Mann; Sara S. Bachman; Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies, Nicotine Tob Res, ; 4(3):1462-2203; 311-9",DALY,Not Stated,Not Stated,"Health Education or Behavior, Legislation / Regulation, Pharmaceutical",Nicotine replacement therapy (NRT) with effectiveness of 2.5% (low-end estimate) vs. None,current smokers,Not Stated,Not Stated,"Female, Male",Full,", 50",3.00,3,203,United States,1997,327.34
25635,Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies,"The objective of this study was to provide conservative estimates of the global and regional effectiveness and cost-effectiveness of tobacco control policies. Using a static model of the cohort of smokers alive in 1995, we estimated the number of smoking-attributable deaths that could be averted by: (1) price increases, (2) nicotine replacement therapy (NRT), and (3) a package of non-price interventions other than NRT. We calculated the cost-effectiveness of these policy interventions by weighing the approximate public-sector costs against the years of healthy life saved, measured in disability-adjusted life years, or DALYs. Even with deliberately conservative assumptions, tax increases that would raise the real price of cigarettes by 10% worldwide would prevent between 5 and 16 million tobacco-related deaths, and could cost 3-70 US dollars per DALY saved in low-income and middle-income regions. NRT and a package of non-price interventions other than NRT are also cost-effective in low-income and middle-income regions, at 280-870 US dollars per DALY and 36-710 US dollars per DALY, respectively. In high-income countries, price increases were found to have a cost-effectiveness of 83-2771 US dollars per DALY, NRT 750-7206 US dollars per DALY and other non-price interventions 696-13,924 US dollars per DALY. Tobacco control policies, particularly tax increases on cigarettes, are cost-effective relative to other health interventions. Our estimates are subject to considerable variation in actual settings; thus, local cost-effectiveness studies are required to guide local policy.",2002-01-0508,12215240,Nicotine Tob Res,M Kent Ranson,2002,4 / 3,311-9,No,12215240,"M Kent Ranson; Prabhat Jha; Frank J Chaloupka; Son N Nguyen; Reem M. Ghandour; Meg Comeau; Carol Tobias; Beth Dworetzky; Rose Hamershock; Lynda Honberg; Marie Y. Mann; Sara S. Bachman; Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies, Nicotine Tob Res, ; 4(3):1462-2203; 311-9",DALY,Not Stated,Not Stated,"Health Education or Behavior, Legislation / Regulation, Pharmaceutical",Nicotine replacement therapy (NRT) with effectiveness of 2.5% (low-end estimate) vs. None,current smokers,Not Stated,Not Stated,"Female, Male",Full,", 50",3.00,3,289,United States,1997,466.02
25636,Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies,"The objective of this study was to provide conservative estimates of the global and regional effectiveness and cost-effectiveness of tobacco control policies. Using a static model of the cohort of smokers alive in 1995, we estimated the number of smoking-attributable deaths that could be averted by: (1) price increases, (2) nicotine replacement therapy (NRT), and (3) a package of non-price interventions other than NRT. We calculated the cost-effectiveness of these policy interventions by weighing the approximate public-sector costs against the years of healthy life saved, measured in disability-adjusted life years, or DALYs. Even with deliberately conservative assumptions, tax increases that would raise the real price of cigarettes by 10% worldwide would prevent between 5 and 16 million tobacco-related deaths, and could cost 3-70 US dollars per DALY saved in low-income and middle-income regions. NRT and a package of non-price interventions other than NRT are also cost-effective in low-income and middle-income regions, at 280-870 US dollars per DALY and 36-710 US dollars per DALY, respectively. In high-income countries, price increases were found to have a cost-effectiveness of 83-2771 US dollars per DALY, NRT 750-7206 US dollars per DALY and other non-price interventions 696-13,924 US dollars per DALY. Tobacco control policies, particularly tax increases on cigarettes, are cost-effective relative to other health interventions. Our estimates are subject to considerable variation in actual settings; thus, local cost-effectiveness studies are required to guide local policy.",2002-01-0508,12215240,Nicotine Tob Res,M Kent Ranson,2002,4 / 3,311-9,No,12215240,"M Kent Ranson; Prabhat Jha; Frank J Chaloupka; Son N Nguyen; Reem M. Ghandour; Meg Comeau; Carol Tobias; Beth Dworetzky; Rose Hamershock; Lynda Honberg; Marie Y. Mann; Sara S. Bachman; Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies, Nicotine Tob Res, ; 4(3):1462-2203; 311-9",DALY,Not Stated,Not Stated,"Health Education or Behavior, Legislation / Regulation, Pharmaceutical",Nicotine replacement therapy (NRT) with effectiveness of 2.5% (low-end estimate) vs. None,current smokers,Not Stated,Not Stated,"Female, Male",Full,", 50",3.00,3,216,United States,1997,348.31
25637,Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies,"The objective of this study was to provide conservative estimates of the global and regional effectiveness and cost-effectiveness of tobacco control policies. Using a static model of the cohort of smokers alive in 1995, we estimated the number of smoking-attributable deaths that could be averted by: (1) price increases, (2) nicotine replacement therapy (NRT), and (3) a package of non-price interventions other than NRT. We calculated the cost-effectiveness of these policy interventions by weighing the approximate public-sector costs against the years of healthy life saved, measured in disability-adjusted life years, or DALYs. Even with deliberately conservative assumptions, tax increases that would raise the real price of cigarettes by 10% worldwide would prevent between 5 and 16 million tobacco-related deaths, and could cost 3-70 US dollars per DALY saved in low-income and middle-income regions. NRT and a package of non-price interventions other than NRT are also cost-effective in low-income and middle-income regions, at 280-870 US dollars per DALY and 36-710 US dollars per DALY, respectively. In high-income countries, price increases were found to have a cost-effectiveness of 83-2771 US dollars per DALY, NRT 750-7206 US dollars per DALY and other non-price interventions 696-13,924 US dollars per DALY. Tobacco control policies, particularly tax increases on cigarettes, are cost-effective relative to other health interventions. Our estimates are subject to considerable variation in actual settings; thus, local cost-effectiveness studies are required to guide local policy.",2002-01-0508,12215240,Nicotine Tob Res,M Kent Ranson,2002,4 / 3,311-9,No,12215240,"M Kent Ranson; Prabhat Jha; Frank J Chaloupka; Son N Nguyen; Reem M. Ghandour; Meg Comeau; Carol Tobias; Beth Dworetzky; Rose Hamershock; Lynda Honberg; Marie Y. Mann; Sara S. Bachman; Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies, Nicotine Tob Res, ; 4(3):1462-2203; 311-9",DALY,Not Stated,Not Stated,"Health Education or Behavior, Legislation / Regulation, Pharmaceutical",Nicotine replacement therapy (NRT) with effectiveness of 2.5% (low-end estimate) vs. None,current smokers,Not Stated,Not Stated,"Female, Male",Full,", 50",3.00,3,280,United States,1997,451.51
25638,Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies,"The objective of this study was to provide conservative estimates of the global and regional effectiveness and cost-effectiveness of tobacco control policies. Using a static model of the cohort of smokers alive in 1995, we estimated the number of smoking-attributable deaths that could be averted by: (1) price increases, (2) nicotine replacement therapy (NRT), and (3) a package of non-price interventions other than NRT. We calculated the cost-effectiveness of these policy interventions by weighing the approximate public-sector costs against the years of healthy life saved, measured in disability-adjusted life years, or DALYs. Even with deliberately conservative assumptions, tax increases that would raise the real price of cigarettes by 10% worldwide would prevent between 5 and 16 million tobacco-related deaths, and could cost 3-70 US dollars per DALY saved in low-income and middle-income regions. NRT and a package of non-price interventions other than NRT are also cost-effective in low-income and middle-income regions, at 280-870 US dollars per DALY and 36-710 US dollars per DALY, respectively. In high-income countries, price increases were found to have a cost-effectiveness of 83-2771 US dollars per DALY, NRT 750-7206 US dollars per DALY and other non-price interventions 696-13,924 US dollars per DALY. Tobacco control policies, particularly tax increases on cigarettes, are cost-effective relative to other health interventions. Our estimates are subject to considerable variation in actual settings; thus, local cost-effectiveness studies are required to guide local policy.",2002-01-0508,12215240,Nicotine Tob Res,M Kent Ranson,2002,4 / 3,311-9,No,12215240,"M Kent Ranson; Prabhat Jha; Frank J Chaloupka; Son N Nguyen; Reem M. Ghandour; Meg Comeau; Carol Tobias; Beth Dworetzky; Rose Hamershock; Lynda Honberg; Marie Y. Mann; Sara S. Bachman; Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies, Nicotine Tob Res, ; 4(3):1462-2203; 311-9",DALY,Not Stated,Not Stated,"Health Education or Behavior, Legislation / Regulation, Pharmaceutical",Nicotine replacement therapy (NRT) with effectiveness of 2.5% (low-end estimate) vs. None,current smokers,Not Stated,Not Stated,"Female, Male",Full,", 50",3.00,3,750,United States,1997,1209.4
25639,Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies,"The objective of this study was to provide conservative estimates of the global and regional effectiveness and cost-effectiveness of tobacco control policies. Using a static model of the cohort of smokers alive in 1995, we estimated the number of smoking-attributable deaths that could be averted by: (1) price increases, (2) nicotine replacement therapy (NRT), and (3) a package of non-price interventions other than NRT. We calculated the cost-effectiveness of these policy interventions by weighing the approximate public-sector costs against the years of healthy life saved, measured in disability-adjusted life years, or DALYs. Even with deliberately conservative assumptions, tax increases that would raise the real price of cigarettes by 10% worldwide would prevent between 5 and 16 million tobacco-related deaths, and could cost 3-70 US dollars per DALY saved in low-income and middle-income regions. NRT and a package of non-price interventions other than NRT are also cost-effective in low-income and middle-income regions, at 280-870 US dollars per DALY and 36-710 US dollars per DALY, respectively. In high-income countries, price increases were found to have a cost-effectiveness of 83-2771 US dollars per DALY, NRT 750-7206 US dollars per DALY and other non-price interventions 696-13,924 US dollars per DALY. Tobacco control policies, particularly tax increases on cigarettes, are cost-effective relative to other health interventions. Our estimates are subject to considerable variation in actual settings; thus, local cost-effectiveness studies are required to guide local policy.",2002-01-0508,12215240,Nicotine Tob Res,M Kent Ranson,2002,4 / 3,311-9,No,12215240,"M Kent Ranson; Prabhat Jha; Frank J Chaloupka; Son N Nguyen; Reem M. Ghandour; Meg Comeau; Carol Tobias; Beth Dworetzky; Rose Hamershock; Lynda Honberg; Marie Y. Mann; Sara S. Bachman; Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies, Nicotine Tob Res, ; 4(3):1462-2203; 311-9",DALY,Not Stated,Not Stated,"Health Education or Behavior, Legislation / Regulation, Pharmaceutical",Nicotine replacement therapy (NRT) with effectiveness of 2.5% (low-end estimate) vs. None,current smokers,Not Stated,Not Stated,"Female, Male",Full,", 50",3.00,3,358,United States,1997,577.29
25640,Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies,"The objective of this study was to provide conservative estimates of the global and regional effectiveness and cost-effectiveness of tobacco control policies. Using a static model of the cohort of smokers alive in 1995, we estimated the number of smoking-attributable deaths that could be averted by: (1) price increases, (2) nicotine replacement therapy (NRT), and (3) a package of non-price interventions other than NRT. We calculated the cost-effectiveness of these policy interventions by weighing the approximate public-sector costs against the years of healthy life saved, measured in disability-adjusted life years, or DALYs. Even with deliberately conservative assumptions, tax increases that would raise the real price of cigarettes by 10% worldwide would prevent between 5 and 16 million tobacco-related deaths, and could cost 3-70 US dollars per DALY saved in low-income and middle-income regions. NRT and a package of non-price interventions other than NRT are also cost-effective in low-income and middle-income regions, at 280-870 US dollars per DALY and 36-710 US dollars per DALY, respectively. In high-income countries, price increases were found to have a cost-effectiveness of 83-2771 US dollars per DALY, NRT 750-7206 US dollars per DALY and other non-price interventions 696-13,924 US dollars per DALY. Tobacco control policies, particularly tax increases on cigarettes, are cost-effective relative to other health interventions. Our estimates are subject to considerable variation in actual settings; thus, local cost-effectiveness studies are required to guide local policy.",2002-01-0508,12215240,Nicotine Tob Res,M Kent Ranson,2002,4 / 3,311-9,No,12215240,"M Kent Ranson; Prabhat Jha; Frank J Chaloupka; Son N Nguyen; Reem M. Ghandour; Meg Comeau; Carol Tobias; Beth Dworetzky; Rose Hamershock; Lynda Honberg; Marie Y. Mann; Sara S. Bachman; Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies, Nicotine Tob Res, ; 4(3):1462-2203; 311-9",DALY,Not Stated,Not Stated,"Health Education or Behavior, Legislation / Regulation, Pharmaceutical","Non-price interventions, other than nicotine replacement therapy (NRT) (low-end estimate) including complete bans on advertising and promotion of all tobacco products related logos or trademarks, dissemination of information on the health consequences of smoking and restrictions on smoking in public places and work places vs. None",current smokers,Not Stated,Not Stated,"Female, Male",Full,", 50",3.00,3,25,United States,1997,40.31
25641,Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies,"The objective of this study was to provide conservative estimates of the global and regional effectiveness and cost-effectiveness of tobacco control policies. Using a static model of the cohort of smokers alive in 1995, we estimated the number of smoking-attributable deaths that could be averted by: (1) price increases, (2) nicotine replacement therapy (NRT), and (3) a package of non-price interventions other than NRT. We calculated the cost-effectiveness of these policy interventions by weighing the approximate public-sector costs against the years of healthy life saved, measured in disability-adjusted life years, or DALYs. Even with deliberately conservative assumptions, tax increases that would raise the real price of cigarettes by 10% worldwide would prevent between 5 and 16 million tobacco-related deaths, and could cost 3-70 US dollars per DALY saved in low-income and middle-income regions. NRT and a package of non-price interventions other than NRT are also cost-effective in low-income and middle-income regions, at 280-870 US dollars per DALY and 36-710 US dollars per DALY, respectively. In high-income countries, price increases were found to have a cost-effectiveness of 83-2771 US dollars per DALY, NRT 750-7206 US dollars per DALY and other non-price interventions 696-13,924 US dollars per DALY. Tobacco control policies, particularly tax increases on cigarettes, are cost-effective relative to other health interventions. Our estimates are subject to considerable variation in actual settings; thus, local cost-effectiveness studies are required to guide local policy.",2002-01-0508,12215240,Nicotine Tob Res,M Kent Ranson,2002,4 / 3,311-9,No,12215240,"M Kent Ranson; Prabhat Jha; Frank J Chaloupka; Son N Nguyen; Reem M. Ghandour; Meg Comeau; Carol Tobias; Beth Dworetzky; Rose Hamershock; Lynda Honberg; Marie Y. Mann; Sara S. Bachman; Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies, Nicotine Tob Res, ; 4(3):1462-2203; 311-9",DALY,Not Stated,Not Stated,"Health Education or Behavior, Legislation / Regulation, Pharmaceutical","Non-price interventions, other than nicotine replacement therapy (NRT) (low-end estimate) including complete bans on advertising and promotion of all tobacco products related logos or trademarks, dissemination of information on the health consequences of smoking and restrictions on smoking in public places and work places vs. None",current smokers,Not Stated,Not Stated,"Female, Male",Full,", 50",3.00,3,39,United States,1997,62.89
25642,Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies,"The objective of this study was to provide conservative estimates of the global and regional effectiveness and cost-effectiveness of tobacco control policies. Using a static model of the cohort of smokers alive in 1995, we estimated the number of smoking-attributable deaths that could be averted by: (1) price increases, (2) nicotine replacement therapy (NRT), and (3) a package of non-price interventions other than NRT. We calculated the cost-effectiveness of these policy interventions by weighing the approximate public-sector costs against the years of healthy life saved, measured in disability-adjusted life years, or DALYs. Even with deliberately conservative assumptions, tax increases that would raise the real price of cigarettes by 10% worldwide would prevent between 5 and 16 million tobacco-related deaths, and could cost 3-70 US dollars per DALY saved in low-income and middle-income regions. NRT and a package of non-price interventions other than NRT are also cost-effective in low-income and middle-income regions, at 280-870 US dollars per DALY and 36-710 US dollars per DALY, respectively. In high-income countries, price increases were found to have a cost-effectiveness of 83-2771 US dollars per DALY, NRT 750-7206 US dollars per DALY and other non-price interventions 696-13,924 US dollars per DALY. Tobacco control policies, particularly tax increases on cigarettes, are cost-effective relative to other health interventions. Our estimates are subject to considerable variation in actual settings; thus, local cost-effectiveness studies are required to guide local policy.",2002-01-0508,12215240,Nicotine Tob Res,M Kent Ranson,2002,4 / 3,311-9,No,12215240,"M Kent Ranson; Prabhat Jha; Frank J Chaloupka; Son N Nguyen; Reem M. Ghandour; Meg Comeau; Carol Tobias; Beth Dworetzky; Rose Hamershock; Lynda Honberg; Marie Y. Mann; Sara S. Bachman; Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies, Nicotine Tob Res, ; 4(3):1462-2203; 311-9",DALY,Not Stated,Not Stated,"Health Education or Behavior, Legislation / Regulation, Pharmaceutical","Non-price interventions, other than nicotine replacement therapy (NRT) (low-end estimate) including complete bans on advertising and promotion of all tobacco products related logos or trademarks, dissemination of information on the health consequences of smoking and restrictions on smoking in public places and work places vs. None",current smokers,Not Stated,Not Stated,"Female, Male",Full,", 50",3.00,3,84,United States,1997,135.45
25643,Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies,"The objective of this study was to provide conservative estimates of the global and regional effectiveness and cost-effectiveness of tobacco control policies. Using a static model of the cohort of smokers alive in 1995, we estimated the number of smoking-attributable deaths that could be averted by: (1) price increases, (2) nicotine replacement therapy (NRT), and (3) a package of non-price interventions other than NRT. We calculated the cost-effectiveness of these policy interventions by weighing the approximate public-sector costs against the years of healthy life saved, measured in disability-adjusted life years, or DALYs. Even with deliberately conservative assumptions, tax increases that would raise the real price of cigarettes by 10% worldwide would prevent between 5 and 16 million tobacco-related deaths, and could cost 3-70 US dollars per DALY saved in low-income and middle-income regions. NRT and a package of non-price interventions other than NRT are also cost-effective in low-income and middle-income regions, at 280-870 US dollars per DALY and 36-710 US dollars per DALY, respectively. In high-income countries, price increases were found to have a cost-effectiveness of 83-2771 US dollars per DALY, NRT 750-7206 US dollars per DALY and other non-price interventions 696-13,924 US dollars per DALY. Tobacco control policies, particularly tax increases on cigarettes, are cost-effective relative to other health interventions. Our estimates are subject to considerable variation in actual settings; thus, local cost-effectiveness studies are required to guide local policy.",2002-01-0508,12215240,Nicotine Tob Res,M Kent Ranson,2002,4 / 3,311-9,No,12215240,"M Kent Ranson; Prabhat Jha; Frank J Chaloupka; Son N Nguyen; Reem M. Ghandour; Meg Comeau; Carol Tobias; Beth Dworetzky; Rose Hamershock; Lynda Honberg; Marie Y. Mann; Sara S. Bachman; Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies, Nicotine Tob Res, ; 4(3):1462-2203; 311-9",DALY,Not Stated,Not Stated,"Health Education or Behavior, Legislation / Regulation, Pharmaceutical","Non-price interventions, other than nicotine replacement therapy (NRT) (low-end estimate) including complete bans on advertising and promotion of all tobacco products related logos or trademarks, dissemination of information on the health consequences of smoking and restrictions on smoking in public places and work places vs. None",current smokers,Not Stated,Not Stated,"Female, Male",Full,", 50",3.00,3,58,United States,1997,93.53
25644,Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies,"The objective of this study was to provide conservative estimates of the global and regional effectiveness and cost-effectiveness of tobacco control policies. Using a static model of the cohort of smokers alive in 1995, we estimated the number of smoking-attributable deaths that could be averted by: (1) price increases, (2) nicotine replacement therapy (NRT), and (3) a package of non-price interventions other than NRT. We calculated the cost-effectiveness of these policy interventions by weighing the approximate public-sector costs against the years of healthy life saved, measured in disability-adjusted life years, or DALYs. Even with deliberately conservative assumptions, tax increases that would raise the real price of cigarettes by 10% worldwide would prevent between 5 and 16 million tobacco-related deaths, and could cost 3-70 US dollars per DALY saved in low-income and middle-income regions. NRT and a package of non-price interventions other than NRT are also cost-effective in low-income and middle-income regions, at 280-870 US dollars per DALY and 36-710 US dollars per DALY, respectively. In high-income countries, price increases were found to have a cost-effectiveness of 83-2771 US dollars per DALY, NRT 750-7206 US dollars per DALY and other non-price interventions 696-13,924 US dollars per DALY. Tobacco control policies, particularly tax increases on cigarettes, are cost-effective relative to other health interventions. Our estimates are subject to considerable variation in actual settings; thus, local cost-effectiveness studies are required to guide local policy.",2002-01-0508,12215240,Nicotine Tob Res,M Kent Ranson,2002,4 / 3,311-9,No,12215240,"M Kent Ranson; Prabhat Jha; Frank J Chaloupka; Son N Nguyen; Reem M. Ghandour; Meg Comeau; Carol Tobias; Beth Dworetzky; Rose Hamershock; Lynda Honberg; Marie Y. Mann; Sara S. Bachman; Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies, Nicotine Tob Res, ; 4(3):1462-2203; 311-9",DALY,Not Stated,Not Stated,"Health Education or Behavior, Legislation / Regulation, Pharmaceutical","Non-price interventions, other than nicotine replacement therapy (NRT) (low-end estimate) including complete bans on advertising and promotion of all tobacco products related logos or trademarks, dissemination of information on the health consequences of smoking and restrictions on smoking in public places and work places vs. None",current smokers,Not Stated,Not Stated,"Female, Male",Full,", 50",3.00,3,16,United States,1997,25.8
25645,Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies,"The objective of this study was to provide conservative estimates of the global and regional effectiveness and cost-effectiveness of tobacco control policies. Using a static model of the cohort of smokers alive in 1995, we estimated the number of smoking-attributable deaths that could be averted by: (1) price increases, (2) nicotine replacement therapy (NRT), and (3) a package of non-price interventions other than NRT. We calculated the cost-effectiveness of these policy interventions by weighing the approximate public-sector costs against the years of healthy life saved, measured in disability-adjusted life years, or DALYs. Even with deliberately conservative assumptions, tax increases that would raise the real price of cigarettes by 10% worldwide would prevent between 5 and 16 million tobacco-related deaths, and could cost 3-70 US dollars per DALY saved in low-income and middle-income regions. NRT and a package of non-price interventions other than NRT are also cost-effective in low-income and middle-income regions, at 280-870 US dollars per DALY and 36-710 US dollars per DALY, respectively. In high-income countries, price increases were found to have a cost-effectiveness of 83-2771 US dollars per DALY, NRT 750-7206 US dollars per DALY and other non-price interventions 696-13,924 US dollars per DALY. Tobacco control policies, particularly tax increases on cigarettes, are cost-effective relative to other health interventions. Our estimates are subject to considerable variation in actual settings; thus, local cost-effectiveness studies are required to guide local policy.",2002-01-0508,12215240,Nicotine Tob Res,M Kent Ranson,2002,4 / 3,311-9,No,12215240,"M Kent Ranson; Prabhat Jha; Frank J Chaloupka; Son N Nguyen; Reem M. Ghandour; Meg Comeau; Carol Tobias; Beth Dworetzky; Rose Hamershock; Lynda Honberg; Marie Y. Mann; Sara S. Bachman; Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies, Nicotine Tob Res, ; 4(3):1462-2203; 311-9",DALY,Not Stated,Not Stated,"Health Education or Behavior, Legislation / Regulation, Pharmaceutical","Non-price interventions, other than nicotine replacement therapy (NRT) (low-end estimate) including complete bans on advertising and promotion of all tobacco products related logos or trademarks, dissemination of information on the health consequences of smoking and restrictions on smoking in public places and work places vs. None",current smokers,Not Stated,Not Stated,"Female, Male",Full,", 50",3.00,3,23,United States,1997,37.09
25646,Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies,"The objective of this study was to provide conservative estimates of the global and regional effectiveness and cost-effectiveness of tobacco control policies. Using a static model of the cohort of smokers alive in 1995, we estimated the number of smoking-attributable deaths that could be averted by: (1) price increases, (2) nicotine replacement therapy (NRT), and (3) a package of non-price interventions other than NRT. We calculated the cost-effectiveness of these policy interventions by weighing the approximate public-sector costs against the years of healthy life saved, measured in disability-adjusted life years, or DALYs. Even with deliberately conservative assumptions, tax increases that would raise the real price of cigarettes by 10% worldwide would prevent between 5 and 16 million tobacco-related deaths, and could cost 3-70 US dollars per DALY saved in low-income and middle-income regions. NRT and a package of non-price interventions other than NRT are also cost-effective in low-income and middle-income regions, at 280-870 US dollars per DALY and 36-710 US dollars per DALY, respectively. In high-income countries, price increases were found to have a cost-effectiveness of 83-2771 US dollars per DALY, NRT 750-7206 US dollars per DALY and other non-price interventions 696-13,924 US dollars per DALY. Tobacco control policies, particularly tax increases on cigarettes, are cost-effective relative to other health interventions. Our estimates are subject to considerable variation in actual settings; thus, local cost-effectiveness studies are required to guide local policy.",2002-01-0508,12215240,Nicotine Tob Res,M Kent Ranson,2002,4 / 3,311-9,No,12215240,"M Kent Ranson; Prabhat Jha; Frank J Chaloupka; Son N Nguyen; Reem M. Ghandour; Meg Comeau; Carol Tobias; Beth Dworetzky; Rose Hamershock; Lynda Honberg; Marie Y. Mann; Sara S. Bachman; Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies, Nicotine Tob Res, ; 4(3):1462-2203; 311-9",DALY,Not Stated,Not Stated,"Health Education or Behavior, Legislation / Regulation, Pharmaceutical","Non-price interventions, other than nicotine replacement therapy (NRT) (low-end estimate) including complete bans on advertising and promotion of all tobacco products related logos or trademarks, dissemination of information on the health consequences of smoking and restrictions on smoking in public places and work places vs. None",current smokers,Not Stated,Not Stated,"Female, Male",Full,", 50",3.00,3,36,United States,1997,58.05
25647,Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies,"The objective of this study was to provide conservative estimates of the global and regional effectiveness and cost-effectiveness of tobacco control policies. Using a static model of the cohort of smokers alive in 1995, we estimated the number of smoking-attributable deaths that could be averted by: (1) price increases, (2) nicotine replacement therapy (NRT), and (3) a package of non-price interventions other than NRT. We calculated the cost-effectiveness of these policy interventions by weighing the approximate public-sector costs against the years of healthy life saved, measured in disability-adjusted life years, or DALYs. Even with deliberately conservative assumptions, tax increases that would raise the real price of cigarettes by 10% worldwide would prevent between 5 and 16 million tobacco-related deaths, and could cost 3-70 US dollars per DALY saved in low-income and middle-income regions. NRT and a package of non-price interventions other than NRT are also cost-effective in low-income and middle-income regions, at 280-870 US dollars per DALY and 36-710 US dollars per DALY, respectively. In high-income countries, price increases were found to have a cost-effectiveness of 83-2771 US dollars per DALY, NRT 750-7206 US dollars per DALY and other non-price interventions 696-13,924 US dollars per DALY. Tobacco control policies, particularly tax increases on cigarettes, are cost-effective relative to other health interventions. Our estimates are subject to considerable variation in actual settings; thus, local cost-effectiveness studies are required to guide local policy.",2002-01-0508,12215240,Nicotine Tob Res,M Kent Ranson,2002,4 / 3,311-9,No,12215240,"M Kent Ranson; Prabhat Jha; Frank J Chaloupka; Son N Nguyen; Reem M. Ghandour; Meg Comeau; Carol Tobias; Beth Dworetzky; Rose Hamershock; Lynda Honberg; Marie Y. Mann; Sara S. Bachman; Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies, Nicotine Tob Res, ; 4(3):1462-2203; 311-9",DALY,Not Stated,Not Stated,"Health Education or Behavior, Legislation / Regulation, Pharmaceutical","Non-price interventions, other than nicotine replacement therapy (NRT) (low-end estimate) including complete bans on advertising and promotion of all tobacco products related logos or trademarks, dissemination of information on the health consequences of smoking and restrictions on smoking in public places and work places vs. None",current smokers,Not Stated,Not Stated,"Female, Male",Full,", 50",3.00,3,696,United States,1997,1122.32
25648,Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies,"The objective of this study was to provide conservative estimates of the global and regional effectiveness and cost-effectiveness of tobacco control policies. Using a static model of the cohort of smokers alive in 1995, we estimated the number of smoking-attributable deaths that could be averted by: (1) price increases, (2) nicotine replacement therapy (NRT), and (3) a package of non-price interventions other than NRT. We calculated the cost-effectiveness of these policy interventions by weighing the approximate public-sector costs against the years of healthy life saved, measured in disability-adjusted life years, or DALYs. Even with deliberately conservative assumptions, tax increases that would raise the real price of cigarettes by 10% worldwide would prevent between 5 and 16 million tobacco-related deaths, and could cost 3-70 US dollars per DALY saved in low-income and middle-income regions. NRT and a package of non-price interventions other than NRT are also cost-effective in low-income and middle-income regions, at 280-870 US dollars per DALY and 36-710 US dollars per DALY, respectively. In high-income countries, price increases were found to have a cost-effectiveness of 83-2771 US dollars per DALY, NRT 750-7206 US dollars per DALY and other non-price interventions 696-13,924 US dollars per DALY. Tobacco control policies, particularly tax increases on cigarettes, are cost-effective relative to other health interventions. Our estimates are subject to considerable variation in actual settings; thus, local cost-effectiveness studies are required to guide local policy.",2002-01-0508,12215240,Nicotine Tob Res,M Kent Ranson,2002,4 / 3,311-9,No,12215240,"M Kent Ranson; Prabhat Jha; Frank J Chaloupka; Son N Nguyen; Reem M. Ghandour; Meg Comeau; Carol Tobias; Beth Dworetzky; Rose Hamershock; Lynda Honberg; Marie Y. Mann; Sara S. Bachman; Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies, Nicotine Tob Res, ; 4(3):1462-2203; 311-9",DALY,Not Stated,Not Stated,"Health Education or Behavior, Legislation / Regulation, Pharmaceutical","Non-price interventions, other than nicotine replacement therapy (NRT) (low-end estimate) including complete bans on advertising and promotion of all tobacco products related logos or trademarks, dissemination of information on the health consequences of smoking and restrictions on smoking in public places and work places vs. None",current smokers,Not Stated,Not Stated,"Female, Male",Full,", 50",3.00,3,145,United States,1997,233.82
25649,The economic payoffs of integrated malaria control in the Zambian copperbelt between 1930 and 1950,"It has long been suggested that malaria is delaying the economic development of countries that are most severely affected by the disease. Several studies have documented the economic consequences of malaria at the household level, primarily in communities engaged in subsistence farming. A missing element is the appraisal of the economic impact of malaria on the industrial and service sectors that will probably become the backbone of many developing economies. We estimate the economic effects of integrated malaria control implemented during the colonial period and sustained for 20 years in four copper mining communities of the former Northern Rhodesia (now Zambia). Integrated malaria control was characterized by strong emphasis on environmental management, while part of the mining communities also benefited from rapid diagnosis and treatment and the use of bednets. The programmes were highly successful as an estimated 14,122 deaths, 517,284 malaria attacks and 942,347 work shift losses were averted. Overall, 127,226 disability adjusted life years (DALYs) were averted per 3-year incremental period. The cumulative costs of malaria control interventions were 11,169,472 US dollars (in 1995 US dollars). Because the control programmes were so effective, the mining companies attracted a large reservoir of migrant labourers and sustained healthy work forces. The programmes averted an estimated 796,622 US dollars in direct treatment costs and 5,678,745 US dollars in indirect costs as a result of reduced work absenteeism. Within a few years of programme initiation, Northern Rhodesia became the leading copper producer in Africa, and mining generated the dominant share of national income. Copper production and revenues, which increased dramatically during malaria control interventions, amounted to the equivalent of 7.1 billion US dollars (in 1995 US dollars). Integrated malaria control in copper mining communities was a sound investment. It had payoff for public and occupational health, generally, and without it copper extraction and social and economic development would have been impossible.",2002-02-00973,12167093,Trop Med Int Health,Jrg Utzinger,2002,7 / 8,657-77,No,12167093,"Jrg Utzinger; Yesim Tozan; Fadi Doumani; Burton H Singer; The economic payoffs of integrated malaria control in the Zambian copperbelt between 1930 and 1950, Trop Med Int Health, 2002-Aug; 7(8):1360-2276; 657-77",DALY,Zambia,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical","Integrated malaria control including quinine, house screening, oil on water, DDT, mosquito netting in copper mining communities of Roan Antelope vs. Standard/Usual Care",Not Stated,64 Years,6 Years,"Female, Male",Full,,3.00,3,20.66,United States,1995,35.09
25650,The economic payoffs of integrated malaria control in the Zambian copperbelt between 1930 and 1950,"It has long been suggested that malaria is delaying the economic development of countries that are most severely affected by the disease. Several studies have documented the economic consequences of malaria at the household level, primarily in communities engaged in subsistence farming. A missing element is the appraisal of the economic impact of malaria on the industrial and service sectors that will probably become the backbone of many developing economies. We estimate the economic effects of integrated malaria control implemented during the colonial period and sustained for 20 years in four copper mining communities of the former Northern Rhodesia (now Zambia). Integrated malaria control was characterized by strong emphasis on environmental management, while part of the mining communities also benefited from rapid diagnosis and treatment and the use of bednets. The programmes were highly successful as an estimated 14,122 deaths, 517,284 malaria attacks and 942,347 work shift losses were averted. Overall, 127,226 disability adjusted life years (DALYs) were averted per 3-year incremental period. The cumulative costs of malaria control interventions were 11,169,472 US dollars (in 1995 US dollars). Because the control programmes were so effective, the mining companies attracted a large reservoir of migrant labourers and sustained healthy work forces. The programmes averted an estimated 796,622 US dollars in direct treatment costs and 5,678,745 US dollars in indirect costs as a result of reduced work absenteeism. Within a few years of programme initiation, Northern Rhodesia became the leading copper producer in Africa, and mining generated the dominant share of national income. Copper production and revenues, which increased dramatically during malaria control interventions, amounted to the equivalent of 7.1 billion US dollars (in 1995 US dollars). Integrated malaria control in copper mining communities was a sound investment. It had payoff for public and occupational health, generally, and without it copper extraction and social and economic development would have been impossible.",2002-02-00973,12167093,Trop Med Int Health,Jrg Utzinger,2002,7 / 8,657-77,No,12167093,"Jrg Utzinger; Yesim Tozan; Fadi Doumani; Burton H Singer; The economic payoffs of integrated malaria control in the Zambian copperbelt between 1930 and 1950, Trop Med Int Health, 2002-Aug; 7(8):1360-2276; 657-77",DALY,Zambia,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical","Integrated malaria control including quinine, house screening, oil on water, DDT, mosquito netting in copper mining communities of Mufulira vs. Standard/Usual Care",Not Stated,64 Years,6 Years,"Female, Male",Full,,3.00,3,39.35,United States,1995,66.83
25651,The economic payoffs of integrated malaria control in the Zambian copperbelt between 1930 and 1950,"It has long been suggested that malaria is delaying the economic development of countries that are most severely affected by the disease. Several studies have documented the economic consequences of malaria at the household level, primarily in communities engaged in subsistence farming. A missing element is the appraisal of the economic impact of malaria on the industrial and service sectors that will probably become the backbone of many developing economies. We estimate the economic effects of integrated malaria control implemented during the colonial period and sustained for 20 years in four copper mining communities of the former Northern Rhodesia (now Zambia). Integrated malaria control was characterized by strong emphasis on environmental management, while part of the mining communities also benefited from rapid diagnosis and treatment and the use of bednets. The programmes were highly successful as an estimated 14,122 deaths, 517,284 malaria attacks and 942,347 work shift losses were averted. Overall, 127,226 disability adjusted life years (DALYs) were averted per 3-year incremental period. The cumulative costs of malaria control interventions were 11,169,472 US dollars (in 1995 US dollars). Because the control programmes were so effective, the mining companies attracted a large reservoir of migrant labourers and sustained healthy work forces. The programmes averted an estimated 796,622 US dollars in direct treatment costs and 5,678,745 US dollars in indirect costs as a result of reduced work absenteeism. Within a few years of programme initiation, Northern Rhodesia became the leading copper producer in Africa, and mining generated the dominant share of national income. Copper production and revenues, which increased dramatically during malaria control interventions, amounted to the equivalent of 7.1 billion US dollars (in 1995 US dollars). Integrated malaria control in copper mining communities was a sound investment. It had payoff for public and occupational health, generally, and without it copper extraction and social and economic development would have been impossible.",2002-02-00973,12167093,Trop Med Int Health,Jrg Utzinger,2002,7 / 8,657-77,No,12167093,"Jrg Utzinger; Yesim Tozan; Fadi Doumani; Burton H Singer; The economic payoffs of integrated malaria control in the Zambian copperbelt between 1930 and 1950, Trop Med Int Health, 2002-Aug; 7(8):1360-2276; 657-77",DALY,Zambia,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical","Integrated malaria control including quinine, house screening, oil on water, DDT, mosquito netting in copper mining communities of Nkana-Kitwe vs. Standard/Usual Care",Not Stated,64 Years,6 Years,"Female, Male",Full,,3.00,3,22.08,United States,1995,37.5
25652,The economic payoffs of integrated malaria control in the Zambian copperbelt between 1930 and 1950,"It has long been suggested that malaria is delaying the economic development of countries that are most severely affected by the disease. Several studies have documented the economic consequences of malaria at the household level, primarily in communities engaged in subsistence farming. A missing element is the appraisal of the economic impact of malaria on the industrial and service sectors that will probably become the backbone of many developing economies. We estimate the economic effects of integrated malaria control implemented during the colonial period and sustained for 20 years in four copper mining communities of the former Northern Rhodesia (now Zambia). Integrated malaria control was characterized by strong emphasis on environmental management, while part of the mining communities also benefited from rapid diagnosis and treatment and the use of bednets. The programmes were highly successful as an estimated 14,122 deaths, 517,284 malaria attacks and 942,347 work shift losses were averted. Overall, 127,226 disability adjusted life years (DALYs) were averted per 3-year incremental period. The cumulative costs of malaria control interventions were 11,169,472 US dollars (in 1995 US dollars). Because the control programmes were so effective, the mining companies attracted a large reservoir of migrant labourers and sustained healthy work forces. The programmes averted an estimated 796,622 US dollars in direct treatment costs and 5,678,745 US dollars in indirect costs as a result of reduced work absenteeism. Within a few years of programme initiation, Northern Rhodesia became the leading copper producer in Africa, and mining generated the dominant share of national income. Copper production and revenues, which increased dramatically during malaria control interventions, amounted to the equivalent of 7.1 billion US dollars (in 1995 US dollars). Integrated malaria control in copper mining communities was a sound investment. It had payoff for public and occupational health, generally, and without it copper extraction and social and economic development would have been impossible.",2002-02-00973,12167093,Trop Med Int Health,Jrg Utzinger,2002,7 / 8,657-77,No,12167093,"Jrg Utzinger; Yesim Tozan; Fadi Doumani; Burton H Singer; The economic payoffs of integrated malaria control in the Zambian copperbelt between 1930 and 1950, Trop Med Int Health, 2002-Aug; 7(8):1360-2276; 657-77",DALY,Zambia,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical","Integrated malaria control including quinine, house screening, oil on water, DDT, mosquito netting in copper mining communities of Nchanga vs. Standard/Usual Care",Not Stated,64 Years,6 Years,"Female, Male",Full,,3.00,3,127.7,United States,1995,216.86
25653,The economic payoffs of integrated malaria control in the Zambian copperbelt between 1930 and 1950,"It has long been suggested that malaria is delaying the economic development of countries that are most severely affected by the disease. Several studies have documented the economic consequences of malaria at the household level, primarily in communities engaged in subsistence farming. A missing element is the appraisal of the economic impact of malaria on the industrial and service sectors that will probably become the backbone of many developing economies. We estimate the economic effects of integrated malaria control implemented during the colonial period and sustained for 20 years in four copper mining communities of the former Northern Rhodesia (now Zambia). Integrated malaria control was characterized by strong emphasis on environmental management, while part of the mining communities also benefited from rapid diagnosis and treatment and the use of bednets. The programmes were highly successful as an estimated 14,122 deaths, 517,284 malaria attacks and 942,347 work shift losses were averted. Overall, 127,226 disability adjusted life years (DALYs) were averted per 3-year incremental period. The cumulative costs of malaria control interventions were 11,169,472 US dollars (in 1995 US dollars). Because the control programmes were so effective, the mining companies attracted a large reservoir of migrant labourers and sustained healthy work forces. The programmes averted an estimated 796,622 US dollars in direct treatment costs and 5,678,745 US dollars in indirect costs as a result of reduced work absenteeism. Within a few years of programme initiation, Northern Rhodesia became the leading copper producer in Africa, and mining generated the dominant share of national income. Copper production and revenues, which increased dramatically during malaria control interventions, amounted to the equivalent of 7.1 billion US dollars (in 1995 US dollars). Integrated malaria control in copper mining communities was a sound investment. It had payoff for public and occupational health, generally, and without it copper extraction and social and economic development would have been impossible.",2002-02-00973,12167093,Trop Med Int Health,Jrg Utzinger,2002,7 / 8,657-77,No,12167093,"Jrg Utzinger; Yesim Tozan; Fadi Doumani; Burton H Singer; The economic payoffs of integrated malaria control in the Zambian copperbelt between 1930 and 1950, Trop Med Int Health, 2002-Aug; 7(8):1360-2276; 657-77",DALY,Zambia,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical","Integrated malaria control including quinine, house screening, oil on water, DDT, mosquito netting in copper mining communities vs. Standard/Usual Care",Not Stated,64 Years,6 Years,"Female, Male",Full,,3.00,3,36.9,United States,1995,62.66
25654,Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru,"There are no data on the feasibility and cost-effectiveness of using second-line drugs to treat patients with chronic tuberculosis, many of whom are infected with multidrug resistant (MDR) strains of Mycobacterium tuberculosis, in low or middle-income countries.A national programme to treat chronic tuberculosis patients with a directly observed standardised 18-month daily regimen, consisting of kanamycin (3 months only), ciprofloxacin, ethionamide, pyrazinamide, and ethambutol, was established in Peru in 1997. Compliance and treatment outcomes were analysed for the cohort started on treatment between October, 1997, and March, 1999. Total and average costs were assessed. Cost-effectiveness was estimated as the cost per DALY gained.466 patients were enrolled; 344 were tested for drug susceptibility and 298 (87%) had MDR tuberculosis. 225 patients (48%) were cured, 57 (12%) died, 131 (28%) did not respond to treatment, and 53 (11%) defaulted. Of the 413 (89%) patients who complied with treatment, 225 (55%) were cured. Among MDR patients, resistance to five or more drugs was significantly associated with an unfavourable outcome (death, non-response to treatment, or default; odds ratio 3.37, 95% CI 1.32-8.60; p=0.01). The programme cost US $0.6 million per year, 8% of the National Tuberculosis Programme budget, and US $2381 per patient for those who completed treatment. The mean cost per DALY gained was $211 ($165 at drug prices projected for 2002).Treating chronic tuberculosis patients with high levels of MDR with second-line drugs can be feasible and cost-effective in middle-income countries, provided a strong tuberculosis control programme is in place.",2002-01-0515,12076553,Lancet,Pedro G Surez,2002,359 / 9322,1980-9,No,12076553,"Pedro G Surez; Katherine Floyd; Jaime Portocarrero; Edith Alarc?n; Elisabetta Rapiti; Gilbert Ramos; Cesar Bonilla; Ivan Sabogal; Isabel Aranda; Christopher Dye; Mario Raviglione; Marcos A Espinal; PG Suarez; K Floyd; J Portocarrero; E Alarcon; E Rapiti; G Ramos; C Bonilla; I Sabogal; E Aranda; C Dye; M Raviglione; MA Espinal; Vasant Hirani; Fiona Blyth; Vasi Naganathan; David G. Le Couteur; Markus J. Seibel; Louise M. Waite; David J. Handelsman; Robert G. Cumming; Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru, Lancet, ; 359(9322):0140-6736; 1980-9",DALY,Peru,Not Stated,Pharmaceutical,"Second line treatment: kanamycin (1 g injectable for the first three months), ciprofloxacin (1 g orally), ethionamide (750 mg orally), pyrazinamide (1500 mg orally), and etambutol (1200 mg orally) for 18 months vs. first line treatment (isoniazid monotherapy)","sputum-smear positive patients after completing a fully supervised treatment regimen, or exceptions where previous treatment had not been administered under direct observation",Not Stated,Not Stated,"Female, Male",Full,,Not Stated,3,211,United States,2000,317.13
25655,Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru,"There are no data on the feasibility and cost-effectiveness of using second-line drugs to treat patients with chronic tuberculosis, many of whom are infected with multidrug resistant (MDR) strains of Mycobacterium tuberculosis, in low or middle-income countries.A national programme to treat chronic tuberculosis patients with a directly observed standardised 18-month daily regimen, consisting of kanamycin (3 months only), ciprofloxacin, ethionamide, pyrazinamide, and ethambutol, was established in Peru in 1997. Compliance and treatment outcomes were analysed for the cohort started on treatment between October, 1997, and March, 1999. Total and average costs were assessed. Cost-effectiveness was estimated as the cost per DALY gained.466 patients were enrolled; 344 were tested for drug susceptibility and 298 (87%) had MDR tuberculosis. 225 patients (48%) were cured, 57 (12%) died, 131 (28%) did not respond to treatment, and 53 (11%) defaulted. Of the 413 (89%) patients who complied with treatment, 225 (55%) were cured. Among MDR patients, resistance to five or more drugs was significantly associated with an unfavourable outcome (death, non-response to treatment, or default; odds ratio 3.37, 95% CI 1.32-8.60; p=0.01). The programme cost US $0.6 million per year, 8% of the National Tuberculosis Programme budget, and US $2381 per patient for those who completed treatment. The mean cost per DALY gained was $211 ($165 at drug prices projected for 2002).Treating chronic tuberculosis patients with high levels of MDR with second-line drugs can be feasible and cost-effective in middle-income countries, provided a strong tuberculosis control programme is in place.",2002-01-0515,12076553,Lancet,Pedro G Surez,2002,359 / 9322,1980-9,No,12076553,"Pedro G Surez; Katherine Floyd; Jaime Portocarrero; Edith Alarc?n; Elisabetta Rapiti; Gilbert Ramos; Cesar Bonilla; Ivan Sabogal; Isabel Aranda; Christopher Dye; Mario Raviglione; Marcos A Espinal; PG Suarez; K Floyd; J Portocarrero; E Alarcon; E Rapiti; G Ramos; C Bonilla; I Sabogal; E Aranda; C Dye; M Raviglione; MA Espinal; Vasant Hirani; Fiona Blyth; Vasi Naganathan; David G. Le Couteur; Markus J. Seibel; Louise M. Waite; David J. Handelsman; Robert G. Cumming; Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru, Lancet, ; 359(9322):0140-6736; 1980-9",DALY,Peru,Not Stated,Pharmaceutical,"Second line treatment: kanamycin (1 g injectable for the first three months), ciprofloxacin (1 g orally), ethionamide (750 mg orally), pyrazinamide (1500 mg orally), and etambutol (1200 mg orally) for 18 months, non-responsive patients are given additional option of treatment with individualized regimen tailored to their drug susceptibility pattern vs. first line treatment (isoniazid monotherapy)","sputum-smear positive patients after completing a fully supervised treatment regimen, or exceptions where previous treatment had not been administered under direct observation",Not Stated,Not Stated,"Female, Male",Full,,Not Stated,3,368,United States,2000,553.09
25656,Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru,"There are no data on the feasibility and cost-effectiveness of using second-line drugs to treat patients with chronic tuberculosis, many of whom are infected with multidrug resistant (MDR) strains of Mycobacterium tuberculosis, in low or middle-income countries.A national programme to treat chronic tuberculosis patients with a directly observed standardised 18-month daily regimen, consisting of kanamycin (3 months only), ciprofloxacin, ethionamide, pyrazinamide, and ethambutol, was established in Peru in 1997. Compliance and treatment outcomes were analysed for the cohort started on treatment between October, 1997, and March, 1999. Total and average costs were assessed. Cost-effectiveness was estimated as the cost per DALY gained.466 patients were enrolled; 344 were tested for drug susceptibility and 298 (87%) had MDR tuberculosis. 225 patients (48%) were cured, 57 (12%) died, 131 (28%) did not respond to treatment, and 53 (11%) defaulted. Of the 413 (89%) patients who complied with treatment, 225 (55%) were cured. Among MDR patients, resistance to five or more drugs was significantly associated with an unfavourable outcome (death, non-response to treatment, or default; odds ratio 3.37, 95% CI 1.32-8.60; p=0.01). The programme cost US $0.6 million per year, 8% of the National Tuberculosis Programme budget, and US $2381 per patient for those who completed treatment. The mean cost per DALY gained was $211 ($165 at drug prices projected for 2002).Treating chronic tuberculosis patients with high levels of MDR with second-line drugs can be feasible and cost-effective in middle-income countries, provided a strong tuberculosis control programme is in place.",2002-01-0515,12076553,Lancet,Pedro G Surez,2002,359 / 9322,1980-9,No,12076553,"Pedro G Surez; Katherine Floyd; Jaime Portocarrero; Edith Alarc?n; Elisabetta Rapiti; Gilbert Ramos; Cesar Bonilla; Ivan Sabogal; Isabel Aranda; Christopher Dye; Mario Raviglione; Marcos A Espinal; PG Suarez; K Floyd; J Portocarrero; E Alarcon; E Rapiti; G Ramos; C Bonilla; I Sabogal; E Aranda; C Dye; M Raviglione; MA Espinal; Vasant Hirani; Fiona Blyth; Vasi Naganathan; David G. Le Couteur; Markus J. Seibel; Louise M. Waite; David J. Handelsman; Robert G. Cumming; Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru, Lancet, ; 359(9322):0140-6736; 1980-9",DALY,Peru,Not Stated,Pharmaceutical,"Second line treatment: kanamycin (1 g injectable for the first three months), ciprofloxacin (1 g orally), ethionamide (750 mg orally), pyrazinamide (1500 mg orally), and etambutol (1200 mg orally) for 18 months, non-responsive patients are given additional option of treatment with individualized regimen tailored to their drug susceptibility pattern; non-responsive to first-line treatment regimen are tested for MDR and those with MDR (multidrug resistant) tuberculosis are enrolled in the standardized second-line drug treatment vs. first line treatment (isoniazid monotherapy)","sputum-smear positive patients after completing a fully supervised treatment regimen, or exceptions where previous treatment had not been administered under direct observation",Not Stated,Not Stated,"Female, Male",Full,,Not Stated,3,484,United States,2000,727.44
25658,Economic benefits of establishing a National Cancer Center in Louisiana,"This paper estimates the economic benefits of establishing a National Cancer Institute-designated center in Louisiana. Estimates of direct and indirect costs of cancer were used to derive the potential benefits of a cancer center. A fully functional cancer center should be able to prevent about 6,550 deaths over the next 10-year period implying a savings of about 23,000 disability-adjusted life years. The potential revenues to be generated through new patients from neighboring states, diversion of Louisiana patients back to the state from other out-of state facilities, and the indirect benefits derived through increased economic productivity (due to life years saved) makes the establishment of the center highly cost-effective. The benefit-cost ratio of establishing a cancer center becomes 8.5, i.e., spending one million dollars in a cancer center should generate about dollars 8.5 million worth of economic benefits for the State over a 10-year time horizon.",2003-01-00415,14748486,J La State Med Soc,M Mahmud Khan,2003,155 / 5,"248, 250-4",No,14748486,"M Mahmud Khan; Roy S Weiner; Monika Sawhney; Takahiko Sugihara; Tatsuro Ishizaki; Tadashi Hosoya; Shoko Iga; Waka Yokoyama; Fumio Hirano; Nobuyuki Miyasaka; Masayoshi Harigai; Economic benefits of establishing a National Cancer Center in Louisiana, J La State Med Soc, ; 155(5):0024-6921; 248, 250-4",DALY,United States of America,Not Stated,Care Delivery,Establishing a National Cancer Institute vs. Standard/Usual Care- Inadequate cancer care or seeking care in a different state,Louisiana,Not Stated,19 Years,Not Stated,Full,,5.00,5,3185.96,United States,2002,4583.44
25659,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Salt reduction through voluntary agreements with industry vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,27.33,United States,2000,41.08
25660,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Salt reduction through voluntary agreements with industry vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,44,United States,2000,66.13
25661,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Salt reduction through voluntary agreements with industry vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,37,United States,2000,55.61
25662,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Population-wide reduction in salt intake legislation vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,13,United States,2000,19.54
25663,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Population-wide reduction in salt intake legislation vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,23,United States,2000,34.57
25664,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Population-wide reduction in salt intake legislation vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,19,United States,2000,28.56
25665,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Health Education through mass media vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,14,United States,2000,21.04
25666,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Health Education through mass media vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,16,United States,2000,24.05
25667,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Health Education through mass media vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,14,United States,2000,21.04
25668,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Population-wide reduction in salt intake legislation and health education through mass media vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,14,United States,2000,21.04
25669,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Population-wide reduction in salt intake legislation and health education through mass media vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,21,United States,2000,31.56
25670,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Population-wide reduction in salt intake legislation and health education through mass media vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,17,United States,2000,25.55
25671,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Individual-based hypertension treatment and education: treatment of systolic blood pressure above 160 mm Hg with a standard regimen of beta-blocker and diuretic vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,81,United States,2000,121.74
25672,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Individual-based hypertension treatment and education: treatment of systolic blood pressure above 160 mm Hg with a standard regimen of beta-blocker and diuretic vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,203,United States,2000,305.1
25673,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Individual-based hypertension treatment and education: treatment of systolic blood pressure above 160 mm Hg with a standard regimen of beta-blocker and diuretic vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,36,United States,2000,54.11
25674,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Individual-based hypertension treatment and education: treatment of systolic blood pressure above 140 mm Hg with a standard regimen of beta-blocker and diuretic vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,186,United States,2000,279.55
25675,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Individual-based hypertension treatment and education: treatment of systolic blood pressure above 140 mm Hg with a standard regimen of beta-blocker and diuretic vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,454,United States,2000,682.35
25676,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Individual-based hypertension treatment and education: treatment of systolic blood pressure above 140 mm Hg with a standard regimen of beta-blocker and diuretic vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,90,United States,2000,135.27
25677,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Individual treatment for high cholesterol concentration and education: treatment with statins for total cholesterol concentrations above 6-2 mmol/L vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,87,United States,2000,130.76
25678,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Individual treatment for high cholesterol concentration and education: treatment with statins for total cholesterol concentrations above 6-2 mmol/L vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,297,United States,2000,446.38
25679,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Individual treatment for high cholesterol concentration and education: treatment with statins for total cholesterol concentrations above 6-2 mmol/L vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,47,United States,2000,70.64
25680,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Individual treatment for high cholesterol concentration and education: treatment with statins for total cholesterol concentrations above 5-7 mmol/L vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,133,United States,2000,199.89
25681,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Individual treatment for high cholesterol concentration and education: treatment with statins for total cholesterol concentrations above 5-7 mmol/L vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,393,United States,2000,590.67
25682,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Individual treatment for high cholesterol concentration and education: treatment with statins for total cholesterol concentrations above 5-7 mmol/L vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,71,United States,2000,106.71
25683,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Individual treatment and health education for systolic blood pressure and cholesterol concentrations: Treatment thresholds of 140 mm Hg systolic blood pressure and 6-2 mmol/L for total cholesterol concentrations vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,183,United States,2000,275.04
25684,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Individual treatment and health education for systolic blood pressure and cholesterol concentrations: Treatment thresholds of 140 mm Hg systolic blood pressure and 6-2 mmol/L for total cholesterol concentrations vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,516,United States,2000,775.53
25685,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Individual treatment and health education for systolic blood pressure and cholesterol concentrations: Treatment thresholds of 140 mm Hg systolic blood pressure and 6-2 mmol/L for total cholesterol concentrations vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,84,United States,2000,126.25
25686,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Treat patients with multiple risk factors for blood pressure and cholesterol at 25% threshold vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,37,United States,2000,55.61
25687,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Treat patients with multiple risk factors for blood pressure and cholesterol at 15% threshold vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,215,United States,2000,323.14
25688,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Treat patients with multiple risk factors for blood pressure and cholesterol at 15% threshold vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,48,United States,2000,72.14
25689,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Treat patients with multiple risk factors for blood pressure and cholesterol at 5% threshold vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,93,United States,2000,139.78
25690,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Treat patients with multiple risk factors for blood pressure and cholesterol at 15% threshold; salt intake legislation; health education through mass media vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,203,United States,2000,305.1
25691,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Treat patients with multiple risk factors for blood pressure and cholesterol at 15% threshold; salt intake legislation; health education through mass media vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,46,United States,2000,69.14
25692,Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk,"BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding 3.8 mmol/L for 18% and 55%, respectively. We report estimates of the population health effects, and costs of selected interventions to reduce the risks associated with high cholesterol concentrations and blood pressure in areas of the world with differing epidemiological profiles. METHODS: Effect sizes were derived from systematic reviews or meta-analyses, and the effect on health outcomes projected over time for populations with differing age, sex, and epidemiological profiles. Incidence data from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per year worldwide. Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is also cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide. INTERPRETATION: The combination of personal and non-personal health interventions evaluated here could lower the global incidence of cardiovascular events by as much as 50%.",2003-99-00766,12620735,Lancet,C J L Murray,2003,361 / 9359,717-25,No,12620735,"C J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans; Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 2003-Mar-01; 361(9359):0140-6736; 717-25",DALY,"Andorra, Antigua and Barbuda, Argentina, Austria, Bahamas, Bangladesh, Barbados, Belgium, Belize, Bhutan, Brazil, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominica, Dominican Republic, El Salvador, Finland, French Republic, Germany, Greece, Grenada, Guyana, Honduras, Iceland, India, Ireland, Israel, Italy, Jamaica, North Korea, Luxembourg, Maldives, Malta, Mexico, Monaco, Myanmar, Nepal, Netherlands, Norway, Panama, Paraguay, Portugal, San Marino, Slovenia, Spain, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Sweden, Switzerland, Trinidad and Tobago, United Kingdom, Uruguay, Venezuela",Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Treat patients with multiple risk factors for blood pressure and cholesterol at 5% threshold; salt intake legislation; health education through mass media vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3,90,United States,2000,135.27
25693,Costs and benefits of polio eradication: a long-run global perspective,"Pre-vaccination polio incidence rates in USA and Italy were used to predict the cases that would have occurred in the world for the years 1970-2050 in the absence of immunization. Globally, polio program will cost about US dollars 67 billion if vaccination is discontinued after 2010. The medical care cost savings achieved will be more than US dollars 128 billions, implying that polio eradication activities actually pay for itself in the longer run. In addition to the cost savings, the program will prevent 855000 deaths, 4 million paralysis cases and 40 million disability adjusted life years (DALYs) over the years 1970-2050.",2003-99-00826,12531344,Vaccine,M Mahmud Khan,2003,21 / 7-8,702-5,Yes,12531344,"M Mahmud Khan; Jennifer Ehreth; Costs and benefits of polio eradication: a long-run global perspective, Vaccine, 2003-Jan-30; 21(7-8):1873-2518; 702-5",DALY,Not Stated,Not Stated,Immunization,Routine polio vaccination vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,5.00,5,442,United States,2000,664.31
25694,Costs and benefits of polio eradication: a long-run global perspective,"Pre-vaccination polio incidence rates in USA and Italy were used to predict the cases that would have occurred in the world for the years 1970-2050 in the absence of immunization. Globally, polio program will cost about US dollars 67 billion if vaccination is discontinued after 2010. The medical care cost savings achieved will be more than US dollars 128 billions, implying that polio eradication activities actually pay for itself in the longer run. In addition to the cost savings, the program will prevent 855000 deaths, 4 million paralysis cases and 40 million disability adjusted life years (DALYs) over the years 1970-2050.",2003-99-00826,12531344,Vaccine,M Mahmud Khan,2003,21 / 7-8,702-5,Yes,12531344,"M Mahmud Khan; Jennifer Ehreth; Costs and benefits of polio eradication: a long-run global perspective, Vaccine, 2003-Jan-30; 21(7-8):1873-2518; 702-5",DALY,Not Stated,Not Stated,Immunization,Routine polio vaccination vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,5.00,5,-4983.18,United States,2000,-7489.56
25695,Costs and benefits of polio eradication: a long-run global perspective,"Pre-vaccination polio incidence rates in USA and Italy were used to predict the cases that would have occurred in the world for the years 1970-2050 in the absence of immunization. Globally, polio program will cost about US dollars 67 billion if vaccination is discontinued after 2010. The medical care cost savings achieved will be more than US dollars 128 billions, implying that polio eradication activities actually pay for itself in the longer run. In addition to the cost savings, the program will prevent 855000 deaths, 4 million paralysis cases and 40 million disability adjusted life years (DALYs) over the years 1970-2050.",2003-99-00826,12531344,Vaccine,M Mahmud Khan,2003,21 / 7-8,702-5,Yes,12531344,"M Mahmud Khan; Jennifer Ehreth; Costs and benefits of polio eradication: a long-run global perspective, Vaccine, 2003-Jan-30; 21(7-8):1873-2518; 702-5",DALY,Not Stated,Not Stated,Immunization,Routine polio vaccination vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,5.00,5,426,United States,2000,640.26
25696,Costs and benefits of polio eradication: a long-run global perspective,"Pre-vaccination polio incidence rates in USA and Italy were used to predict the cases that would have occurred in the world for the years 1970-2050 in the absence of immunization. Globally, polio program will cost about US dollars 67 billion if vaccination is discontinued after 2010. The medical care cost savings achieved will be more than US dollars 128 billions, implying that polio eradication activities actually pay for itself in the longer run. In addition to the cost savings, the program will prevent 855000 deaths, 4 million paralysis cases and 40 million disability adjusted life years (DALYs) over the years 1970-2050.",2003-99-00826,12531344,Vaccine,M Mahmud Khan,2003,21 / 7-8,702-5,Yes,12531344,"M Mahmud Khan; Jennifer Ehreth; Costs and benefits of polio eradication: a long-run global perspective, Vaccine, 2003-Jan-30; 21(7-8):1873-2518; 702-5",DALY,Not Stated,Not Stated,Immunization,Routine polio vaccination vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,5.00,5,-2779.81,United States,2000,-4177.96
25697,Costs and benefits of polio eradication: a long-run global perspective,"Pre-vaccination polio incidence rates in USA and Italy were used to predict the cases that would have occurred in the world for the years 1970-2050 in the absence of immunization. Globally, polio program will cost about US dollars 67 billion if vaccination is discontinued after 2010. The medical care cost savings achieved will be more than US dollars 128 billions, implying that polio eradication activities actually pay for itself in the longer run. In addition to the cost savings, the program will prevent 855000 deaths, 4 million paralysis cases and 40 million disability adjusted life years (DALYs) over the years 1970-2050.",2003-99-00826,12531344,Vaccine,M Mahmud Khan,2003,21 / 7-8,702-5,Yes,12531344,"M Mahmud Khan; Jennifer Ehreth; Costs and benefits of polio eradication: a long-run global perspective, Vaccine, 2003-Jan-30; 21(7-8):1873-2518; 702-5",DALY,Not Stated,Not Stated,Immunization,Routine polio vaccination vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,5.00,5,1041,United States,2000,1564.59
25698,Costs and benefits of polio eradication: a long-run global perspective,"Pre-vaccination polio incidence rates in USA and Italy were used to predict the cases that would have occurred in the world for the years 1970-2050 in the absence of immunization. Globally, polio program will cost about US dollars 67 billion if vaccination is discontinued after 2010. The medical care cost savings achieved will be more than US dollars 128 billions, implying that polio eradication activities actually pay for itself in the longer run. In addition to the cost savings, the program will prevent 855000 deaths, 4 million paralysis cases and 40 million disability adjusted life years (DALYs) over the years 1970-2050.",2003-99-00826,12531344,Vaccine,M Mahmud Khan,2003,21 / 7-8,702-5,Yes,12531344,"M Mahmud Khan; Jennifer Ehreth; Costs and benefits of polio eradication: a long-run global perspective, Vaccine, 2003-Jan-30; 21(7-8):1873-2518; 702-5",DALY,Not Stated,Not Stated,Immunization,Routine polio vaccination vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,5.00,5,356,United States,2000,535.06
25699,Costs and benefits of polio eradication: a long-run global perspective,"Pre-vaccination polio incidence rates in USA and Italy were used to predict the cases that would have occurred in the world for the years 1970-2050 in the absence of immunization. Globally, polio program will cost about US dollars 67 billion if vaccination is discontinued after 2010. The medical care cost savings achieved will be more than US dollars 128 billions, implying that polio eradication activities actually pay for itself in the longer run. In addition to the cost savings, the program will prevent 855000 deaths, 4 million paralysis cases and 40 million disability adjusted life years (DALYs) over the years 1970-2050.",2003-99-00826,12531344,Vaccine,M Mahmud Khan,2003,21 / 7-8,702-5,Yes,12531344,"M Mahmud Khan; Jennifer Ehreth; Costs and benefits of polio eradication: a long-run global perspective, Vaccine, 2003-Jan-30; 21(7-8):1873-2518; 702-5",DALY,Not Stated,Not Stated,Immunization,Routine polio vaccination vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,5.00,5,-1456.73,United States,2000,-2189.42
25700,Human health benefits from livestock vaccination for brucellosis: case study,"To estimate the economic benefit, cost-effectiveness, and distribution of benefit of improving human health in Mongolia through the control of brucellosis by mass vaccination of livestock.Cost-effectiveness and economic benefit for human society and the agricultural sector of mass vaccination against brucellosis was modelled. The intervention consisted of a planned 10-year livestock mass vaccination campaign using Rev-1 livestock vaccine for small ruminants and S19 livestock vaccine for cattle. Cost-effectiveness, expressed as cost per disability-adjusted life year (DALY) averted, was the primary outcome.In a scenario of 52% reduction of brucellosis transmission between animals achieved by mass vaccination, a total of 49,027 DALYs could be averted. Estimated intervention costs were US$ 8.3 million, and the overall benefit was US$ 26.6 million. This results in a net present value of US$ 18.3 million and an average benefit-cost ratio for society of 3.2 (2.27-4.37). If the costs of the intervention were shared between the sectors in proportion to the benefit to each, the public health sector would contribute 11%, which gives a cost-effectiveness of US$ 19.1 per DALY averted (95% confidence interval 5.3-486.8). If private economic gain because of improved human health was included, the health sector should contribute 42% to the intervention costs and the cost-effectiveness would decrease to US$ 71.4 per DALY averted.If the costs of vaccination of livestock against brucellosis were allocated to all sectors in proportion to the benefits, the intervention might be profitable and cost effective for the agricultural and health sectors.",2003-99-13671,14997239,Bull World Health Organ,Felix Roth,2003,81 / 12,867-76,No,14997239,"Felix Roth; JAKOB Zinsstag; Dontor Orkhon; G Chimed-Ochir; Guy Hutton; Ottorino Cosivi; Guy Carrin; Joachim Otte; Human health benefits from livestock vaccination for brucellosis: case study, Bull World Health Organ, ; 81(12):0042-9686; 867-76",DALY,Mongolia,Not Stated,"Environmental, Health Education or Behavior, Immunization",Mass vaccination of livestock against brucellosis vs. Standard/Usual Care,Not Stated,Not Stated,Not Stated,Not Stated,Full,,5.00,5,19.1,United States,2000,28.71
